Antibodies To Paliperidone And Use Thereof

  *US09465041B2*
  US009465041B2                                 
(12)United States Patent(10)Patent No.: US 9,465,041 B2
  et al. (45) Date of Patent:*Oct.  11, 2016

(54)Antibodies to paliperidone and use thereof 
    
(75)Inventors: Ortho-Clinical Diagnostics, Inc.,  Raritan, NJ (US); 
  Janssen Pharmaceutical NV,  Beerse (BE) 
(73)Assignee:Janssen Pharmaceutica NV,  Beerse (BE), Type: Foreign Company 
(*)Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 193 days. 
  This patent is subject to a terminal disclaimer. 
(21)Appl. No.: 13/971,416 
(22)Filed: Aug.  20, 2013 
(65)Prior Publication Data 
 US 2014/0057298 A1 Feb.  27, 2014 
 Related U.S. Patent Documents 
(60)Provisional application No. 61/691,692, filed on Aug.  21, 2012.
 
Jan.  1, 2013 G 01 N 33 9406 F I Oct.  11, 2016 US B H C Jan.  1, 2013 C 07 K 16 44 L I Oct.  11, 2016 US B H C Jan.  1, 2013 G 01 N 33 9413 L I Oct.  11, 2016 US B H C Jan.  1, 2013 C 07 K 2317 56 L A Oct.  11, 2016 US B H C Jan.  1, 2013 C 07 K 2317 565 L A Oct.  11, 2016 US B H C
(51)Int. Cl. G01N 033/94 (20060101); C07K 016/44 (20060101)
(58)Field of Search  None

 
(56)References Cited
 
 U.S. PATENT DOCUMENTS
 4,166,452  A  9/1979    Generales, Jr.     
 5,120,643  A  6/1992    Ching et al.     
 5,559,041  A  9/1996    Kang et al.     
 5,587,458  A  12/1996    King et al.     
 5,642,870  A  7/1997    Sargis     
 5,714,389  A  2/1998    Charlton et al.     
 5,761,894  A  6/1998    Evans     
 6,034,078  A  3/2000    Fairhurst et al.     
 6,139,800  A  10/2000    Chandler     
 6,228,660  B1  5/2001    May et al.     
 7,163,681  B2  1/2007    Giles-Komar et al.     
 7,416,700  B2  8/2008    Buechler et al.     
 7,772,240  B2  8/2010    Bang-Andersen et al.     
 7,901,949  B2  3/2011    Raj     
 8,058,405  B2  11/2011    Demuth et al.     
 8,088,594  B2  1/2012    Salamone et al.     
 2003//0087306  A1  5/2003    Christensen et al.     
 2003//0143233  A1  7/2003    Goshorn et al.     
 2003//0202975  A1  10/2003    Tedder     
 2004//0127489  A1  7/2004    Pickar et al.     
 2005//0163708  A1  7/2005    Robinson et al.     
 2006//0046967  A1  3/2006    Satyam     
 2006//0235005  A1  10/2006    Goff     
 2006//0251592  A1  11/2006    Hendler et al.     
 2006//0289787  A1  12/2006    Ohman et al.     
 2007//0015290  A1  1/2007    Raj     
 2007//0231883  A1  10/2007    Lindstrom et al.     
 2008//0260812  A1  10/2008    Matsuyama et al.     
 2009//0325193  A1  12/2009    Grenier et al.     
 2010//0069356  A1  3/2010    Gant et al.     
 2010//0111852  A1  5/2010    Yoshida     
 2010//0144781  A1  6/2010    Fu et al.     
 2010//0166502  A1  7/2010    DeMay     
 2010//0203129  A1  8/2010    Andersen et al.     
 2010//0266502  A1  10/2010    Kimura     
 2011//0229979  A1  9/2011    Salamone et al.     
 2011//0230520  A1  9/2011    Sartor et al.     
 2011//0245224  A1  10/2011    Barvian et al.     
 2012//0004165  A1  1/2012    Keil et al.     
 2012//0071636  A1  3/2012    Salamone et al.     
 2014//0057302  A1*2/2014    Hryhorenko 435/7.93

 
 FOREIGN PATENT DOCUMENTS 
 
       EP       0582368       B1                1/2001      
       EP       0583820       B1                3/2002      
       EP       2316468       A1                5/2011      
       EP       2343296       A1                7/2011      
       WO       WO 95/34652       A1                12/1995      
       WO       WO 96/38442       A1                12/1996      
       WO       WO 03/082877       A1                10/2003      
       WO       WO 03/103835       A1                12/2003      
       WO       WO 20/04/014895       A1                2/2004      
       WO       WO 20/05/000901       A2                1/2005      
       WO       WO 20/05/028458       A1                3/2005      
       WO       WO 20/05/033073       A2                4/2005      
       WO       WO 20/05/089082       A2                9/2005      
       WO       WO 20/05/118139       A1                12/2005      
       WO       WO 20/06/137785       A1                12/2006      
       WO       WO 20/09/040409       A1                4/2009      
       WO       WO 20/10/015029       A1                2/2010      
       WO       WO 20/10/104749       A2                9/2010      
       WO       WO-2/010/151711       A1                12/2010      
       WO       WO-2/011/012715       A1                2/2011      
       WO       WO-2/011/042450       A1                4/2011      
       WO       WO 20/11/082076       A1                7/2011      
       WO       WO 20/11/112657       A1                9/2011      
       WO       WO 20/11/115733       A1                9/2011      
       WO       WO 20/11/159537       A2                12/2011      
       WO       WO-2/011/163594       A2                12/2011      
       WO       WO 20/12/003418       A2                1/2012      
       WO       WO 20/12/012595       A2                1/2012      
       WO       WO 20/13/011407       A1                1/2013      
       WO       WO-2/013/024047       A1                2/2013      
       WO       WO-2/013/024048       A1                2/2013      
       WO       WO 20/13/088255       A1                6/2013      
       WO       WO20/14/031584-ISR                         2/2014      

 OTHER PUBLICATIONS
  
  Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. PNAS 1982, vol. 79, pp. 1979-1983. *
  Amit et al. Three-dimensional structure of an antigen-antibody complex at 2.8A resolution. Science 1986, vol. 233, No. 4765, pp. 747-753. *
  International Search Report for corresponding Application No. PCT/US2013/055700 mailed Oct. 10, 2013.
  International Search Report for corresponding Application No. PCT/US2013/055712.
  International Search Report for corresponding Application No. PCT/US2013/055724 mailed Sep. 24, 2013.
  International Search Report for corresponding Application No. PCT/US2013/055729 dated Oct. 31, 2013.
  International Search Report mailed Jan. 16, 2014 for Application No. PCT/US2013/55733.
  International Search Report mailed Mar. 13, 2014 for Application No. PCT/US2013/55775.
  International Search Report mailed Jan. 16, 2014 for Application No. PCT/US2013/55780.
  International Search Report mailed Mar. 10, 2014 for Application No. PCT/US2013/55787.
  International Search Report mailed Jan. 16, 2014 for Application No.
  International Search Report mailed Mar. 10, 2014 for Application No. PCT/US2013/55803.
  International Search Report mailed Jan. 30, 3014 for Application No. PCT/US2013/55817.
  International Search Report mailed Mar. 3, 2014 for Application No. PCT/US2013/55826.
  International Search Report mailed Jan. 16, 2014 for Application No. PCT/US2013/55830.
  International Search Report mailed Mar. 4, 2014 for Application No. PCT/US2013/55834.
  International Search Report mailed Oct. 31, 2013 for Application No. PCT/US2013/055282.
  International Search Report mailed Oct. 11, 2013 for Application No. PCT/US2013/055263.
  U.S. Appl. No. 13/971,387, filed Aug. 20, 2013.
  U.S. Appl. No. 13/971,416, filed Aug. 20, 2013.
  U.S. Appl. No. 13/971,429, filed Aug. 20, 2013.
  U.S. Appl. No. 13/971,448, filed Aug. 20, 2013.
  U.S. Appl. No. 13/971,475, filed Aug. 20, 2013.
  U.S. Appl. No. 13/071,499, filed Aug. 20, 2013.
  U.S. Appl. No. 13/971,519, filed Aug. 20, 2013.
  U.S. Appl. No. 13/971,536, filed Aug. 20, 2013.
  U.S. Appl. No. 13/971,546, filed Aug. 20, 2013.
  U.S. Appl. No. 13/971,562, filed Aug. 20, 3013.
  U.S. Appl. No. 13/970,650, filed Aug. 20, 2013.
  U.S. Appl. No. 13/970,653, filed Aug. 20, 2013.
  U.S. Appl. No. 13/970,660, filed Aug. 20, 2013.
  U.S. Appl. No. 13/970,667, filed Aug. 20, 2013.
  U.S. Appl. No. 13/970,673, filed Aug. 20, 2013.
  U.S. Appl. No. 13/968,465, filed Aug. 20, 2013.
  U.S. Appl. No. 13/968,480, filed Aug. 20, 2013.
  Abdel—Baki, A., et al., “Pharmacotherapy Challenges in Patients with First-Episode Psychosis, Journal of Affective Disorders”, vol. 138, pp. S3-S14 (2012).
  Aliouane, L., et al., “Synthesis of Difluoromethylphosphonamidates by Directed Addition of Amine”, Tetrahedron Letters, vol. 52, pp. 3681-3685 (2011).
  Annuziato, M., et al., “p-Maleimidophenyl Isocyanate: A Novel Heterobifunctional Linker for Hydroxyl to Thiol Coupling”, Bioconjugate Chemistry, vol. 4, pp. 212-218 (1993).
  Billah, Md., et al. “Directed Immobilization of Reduced Antibody Fragments onto a Novel SAM on Gold for Myoglobin Impedance Immunosensing”, Bioelectrochemistry, vol. 80, pp. 49-54 (2010).
  Bodin, A., et al., “Identification and Allergenic Activity of Hydroxyaldehydes-A New Type of Oxidation Product from an Ethylated Non-Ionic Surfactant”, Contact Dermatitis, vol. 44, pp. 207-212 (2001).
  Brinkley, Michael, “A Brief Survey of Methods for Preparing Protein Conjugates with Dyes, Haptens, and Cross-Linking Reagents”, Bioconjugate Chemistry, vol. 3, pp. 2-13 (1992).
  Carter, P., et al., “High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment”, Biotechnology, vol. 10, pp. 163-167.
  Chamow, S., et al., “Conjugation of Soluble CD4 without Loss of Biological Activity via a Novel Carbohydrate-Directed Cross-Linking Reagent”, The Journal of Biological Chemistry, vol. 267, No. 22, Issue of Aug. 5, pp. 15916-15922 (1992).
  Chappey, O., et al., “Monoclonal Antibodies in Hapten Immunossays”, Pharmaceutical Research, vol. 9, No. 11, pp. 1375-1379 (1992).
  Cleland, W. W., “Dithiothreitol, a New Protective Reagent for SH Groups”, Biochemistry, vol. 3, No. 4, pp. 480-482 (1964).
  Dai, R., et al., “A High-Throughput Assay for Evaluating State Dependence and Subtype Selectivity of Cav2 Calcium Channel Inhibitors”, Assay and Drug Development Technologies, vol. 6, No. 2, pp. 195-212 (2008).
  Danilova, N., et al., “Production and Characterization of Anti-Theophylline Monoclonal Antibodies Suitable for Immunoassay”, Immunology Letters, vol. 29, pp. 79-84 (1991).
  Davis, P., et al., “Development and Validation of an LC-MS/MS Method for the Determination of Quetiapine and Four Related Metabolites in Human Plasma”, Journal of Pharmaceutical and Biomedical Analysis, vol. 51, pp. 1113-1119 (2010).
  Diago-Meseguer, J., et al., “A New Reagent for Activating Carboxyl Groups, Preparation and Reactions of N,N-Bis[2-oxo-3-ox-azolidinyl)phosphorodiamidic Chloride”, Syntheses, vol. 7(1), pp. 547-551 (1980).
  Dixon, W.J., “Efficient Analysis of Experimental Observations”, Ann. Rev. Pharmacol. Toxicol., vol. 20, pp. 441-462 (1980).
  Fiedler, H., et al., “Surface Chemical Characterization of Maleic Acid Mono[2-4-alkylpiperazinyl)ethyl esters]. 1. The Complex Adsorption Behavior of an Ampholytic Surfactant”, Langmuir, vol. 10 pp. 3959-3965 (1994).
  Finley, F., et al., “An Integrated Multiassay Approach to the Discovery of Small-Molecule N-Type Voltage-Gated Calcium Channel Antagonists”, Assay and Drug Development Technologies, vol. 8, No. 6, pp. 685-694 (2010)-.
  Gentaur Molecular Products, Data Sheet, Enzyme Immunoassay for the Detection of Olanzapine in Urine or Serum, p. 2 (May 2012).
  Ghetie, V., et al., “Preparation and Characterization of Conjugates of Recombinant CD4 and Deglycosylated Ricin a Chain Using Different Cross-Linkers”, Biocongugate Chemistry, vol. 1, pp. 24-31 (1990).
  Gorja, D., et al., “Novel N-Indolylmethyl Substituted Olanzapine Derivatives: Their Design, Synthesis and Evaluation as PDE4B Inhibitors+”, Organic & Bimolecular Chemistry, vol. 11, pp. 2075-2079 (2013).
  Heykants, J., et al., The Pharmacokinetics of Risperidone in Humans: A Summary, J. Clinical Psychiatry, vol. 55(5), pp. 13-17 (1994).
  Huang, M-L, et al., “Pharmacokinetics of the Novel Antipsychotic Agent Risperidone and the Prolactin Response in Healthy Subjects”, Clinical Pharmacology Therapeutics, vol. 54, pp. 257-268 (1993).
  Huse, W., et al., “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda”:, Research Article, pp. 1275-1281 (Dec. 1989).
  Kim, S., et al., “An Experimental Model for Peripheral Neuropahty Produced by Segmental Spinal Nerve Ligation in the Rat”, Pain, vol. 50, pp. 355-363 (1992).
  Kirley, Terence L, Reduction and Fluorescent Labeling of Cystine-Containing Proteins for Subsequent Structural Analyses, Analytical Biochemistry, vol. 180, pp. 231-236 (1989).
  Kohler, C., et al., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity”, Nature, vol. 256, Aug. 7 (1975) pp. 495-497.
  Konig, W., et al., “A New Method for Synthesizing Peptides: Activation of Carboxyl Molecules With Dicyclohexylcarbodiimide by Adding 1-Hydroxybenzopartriazles”, Chem. Ber. vol. 103, pp. 788-798 (1970).
  Li, Z., et al., “Synthesis and Characteristization of N-Benzoyl-N'-Carboxyalkyl Substituted Thiourea Derivatives”, Phosphorus, Sulfur and Silicon, vol. 178, pp. 293-297 (2003).
  Lieberman, J., et al., “Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia”, The New England Journal of Medicine, vol. 353, pp. 1209-1223 (2005).
  Liu, H., et al., “Organophosphorus Compound DEPBT as a Coupling Reagent for Oligopeptides and Peptoids Synthesis: Studies on Its Mechanism”, Chinese Chemical Letters, vol. 13, No. 7, pp. 601-604 (2002).
  Maddox, D., et al., “Elevated Serum Levels in Human Pregnancy of a Molecule Immunochemically Similar to Eospiophil Granule major Basic Protein”, J. Exp. Medicine, vol. 158, pp. 1211-1226 (1983).
  Malachowski, W., et al. The Chemistry of Phosphapeptides: Formation of Functionalized Phosphonochloridates Under Mild Conditions and Their Reaction With Alcohols and Amines', Journal of Organic Chemistry, vol. 59, pp. 7616-7624 (1994).
  Modena, D., et al, Production and Characterization of Murne Monoclonal Antibodies to Polypeptide Hormones and Their Fragments, Annali Dell'Istitto Superiore di Sanita, vol. 27, No. 1, pp. 167-174 (1991).
  Needleman, S., et al., “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins”, J. Molecular Biology, vol. 48, pp. 443-453 (1970).
  Nielsen, C., et al., “Anti-Allodynic Efficacy of the x-Conopeptide, Xen2174, in Rats with Neuropathic Pain”, Pain, vol. 118, p. 112-124 (2005).
  Nolli, M., et al., “Antibodies Against the Antibiotics: An Overview”, Annali, Istituto Superiore di Sanita, vol. 27, No. 1, pp. 149-154 (1991).
  Park, J., et al., “Novel Cyanine Dyes with Vinylsulfone Group for Labeling Biomolecules”, Bioconjugate Chemistry, pp. 350-362 (2012).
  Penning, T., et al., “Synthesis of Potent Leukotriene A4 . Hydrolase Inhibitors. Identification of 3-[Methyl]4-(phenhlmethyl)phenooxy]propyl]amino]propanoic Acid”, J. Medical Chemistry, vol. 45, pp. 3482-3490 (2002).
  Pruhs, S., et al., “Upscaling the Solid-Phase Synthesis of a Tetrahydrocarabazole in Chemical Development” Organic Process Research & Development, vol. 10, pp. 441-445 (2006).
  Schmid, K., et al., “Distribution of Cyclopropenoid Fatty Acids in Malvaceous Plant Parts”, Phytochemistry, vol. 27, No. 9,pp. 2831-2834 (1988).
  Smith, T., et al., “Comparison of Biosequences”, Advances in Applied Mathematics, vol. 2, pp. 482-489 (1981).
  Su, J., et al., “Modification of the Clozapine structure by Parallel Synthesis”, Bioorganic & Medicinal Chemistry Letters, vol. 16, p. 4548-4553 (2006).
  Subasinghe, N., et al., “A Novel Series of Pyrazolylpiperidine N-Type Calcium Channel Blockers”, Bioorganic & Medicinal Chemistry Letters, vol. 22, pp. 4080-4083 (2012).
  Van Os, J., et al., “Schizophrenia”, Lancet, vol. 374, pp. 635-645 (2009).
  Wilbur, D., et al., Reagents for Astatination of Biomolecules; Comparison of the In Vivo Distribution and Stability of Some Radioiodinated/Astatinated Benzamidyl and nido-Carboranyl Compounds', Bioconjugate Chemistry, vol. 15, pp. 203-223 (2004).
  Woestenborghs, R., et al, “On the Selectivity of Some Recently Developed RIA's”, Methodological Surveys in Biochemistry and Analysis. vol. 20, pp. 241-246 (1990).
  Wu, X., et al. “A New Homobifunctional p-Nitro Phenyl Ester XCoupling Reagent for the Preparation of Neoglycoproteins”, Organic Letters, vol. 6, No. 24, pp. 4407-4410 (2004).
  Alphs et al., “Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial,” Annals of General Psychiatry, 2011, 10(12): 1-10.
  Spina, Edoardo, et al, “The Pharmacology and safety of paliperidone extended-release in the treatment of schizonphrenia”, Expert Opinion on Drug Safety, 2007; 6(6):651-662.
 
 
     * cited by examiner
 
     Primary Examiner —Shafiqul Haq
     Art Unit — 1678
     Exemplary claim number — 1
 
(74)Attorney, Agent, or Firm — Robert DeBarardine; Johnson & Johnson

(57)

Abstract

Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone/paliperidone in a single lateral flow assay device.
18 Claims, 22 Drawing Sheets, and 22 Figures


CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 61/691,692, filed Aug. 21, 2012.

FIELD OF THE INVENTION

[0002] The present invention relates to the field of immunoassays, and in particular to antibodies that bind to paliperidone which can be used in immunoassays for detection of paliperidone.

BACKGROUND

[0003] Schizophrenia is a chronic and debilitating psychiatric disorder affecting approximately 0.45-1% of the world's population (van Os, J.; Kapur, S. “Schizophrenia” Lancet 2009, 374, 635-645). The principal goals of treatment are to achieve sustained remission from psychotic symptoms, reduce the risk and consequences of relapse, and improve patient functioning and overall quality of life. While many patients with schizophrenia are able to achieve symptom stability with the available antipsychotic medications, poor adherence to medication is a common reason for relapse with daily administered oral medications. Several studies (Abdel-Baki, A.; Ouellet-Plamondon, C.; Malla, A. “Pharmacotherapy Challenges in Patients with First-Episode Psychosis” Journal of Affective Disorders 2012, 138, S3-S14) investigating the outcomes of non-compliance have shown that patients with schizophrenia who do not take their medication as prescribed have higher rates of relapse, hospital admission and suicide as well as increased mortality. It is estimated that 40 to 75% of patients with schizophrenia have difficulty adhering to a daily oral treatment regimen (Lieberman, J. A.; Stroup, T. S.; McEvoy, J. P.; Swartz, M. S.; Rosenheck, R. A.; Perkins, D. O.; Keefe, R. S. E.; Davis, S. M.; Davis, C. E.; Lebowitz, B. D.; Severe, J.; Hsiao, J. K. “Effectiveness of Antipyschotic Drugs in Patients with Chronic Schizophrenia” New England Journal of Medicine 2005, 353(12), 1209-1223).
[0004] Therapeutic drug monitoring (TDM) is the quantification of serum or plasma concentrations of drugs, including anti-psychotic drugs, for treatment monitoring and optimization. Such monitoring permits, for example, the identification of patients that are not adhering to their medication regimen, that are not achieving therapeutic doses, that are non-responsive at therapeutic doses, that have suboptimal tolerability, that have pharmacokinetic drug-drug interactions, or that have abnormal metabolism resulting in inappropriate plasma concentrations. Considerable individual variability exists in the patient's ability to absorb, distribute, metabolize, and excrete anti-psychotic drugs. Such differences can be caused by concurrent disease, age, concomitant medication or genetic peculiarities. Different drug formulations can also influence the metabolism of anti-psychotic drugs. TDM permits dose optimization for individual patients, improving therapeutic and functional outcomes. TDM further permits a prescribing clinician to ensure compliance with prescribed dosages and achievement of effective serum concentrations.
[0005] To date, methods for determining the levels of serum or plasma concentrations of anti-psychotic drugs involve the use of liquid chromatography (LC) with UV or mass spectrometry detection, and radioimmunoassays (see, for example, Woestenborghs et al., 1990 “On the selectivity of some recently developed RIA's” in Methodological Surveys in Biochemistry and Analysis 20:241-246. Analysis of Drugs and Metabolites, Including Anti-infective Agents; Heykants et al., 1994 “The Pharmacokinetics of Risperidone in Humans: A Summary”, J Clin Psychiatry 55/5, suppl:13-17; Huang et al., 1993 “Pharmacokinetics of the novel anti-psychotic agent risperidone and the prolactin response in healthy subjects”, Clin Pharmacol Ther 54:257-268). Radioimmunoassays detect one or both of risperidone and paliperidone. Salamone et al. in U.S. Pat. No. 8,088,594 disclose a competitive immunoassay for risperidone using antibodies that detect both risperidone and paliperidone but not pharmacologically inactive metabolites. The antibodies used in the competitive immunoassay are developed against a particular immunogen. ID Labs Inc. (London, Ontario, Canada) markets an ELISA for olanzapine, another anti-psychotic drug, which also utilizes a competitive format. The Instructions For Use indicate that the assay is designed for screening purposes and intended for forensic or research use, and is specifically not intended for therapeutic use. The Instructions recommend that all positive samples should be confirmed with gas chromatography/mass spectrometry (GC-MS), and indicate that the antibody used detects olanzapine and clozapine (see ID Labs Inc., “Instructions For Use Data Sheet IDEL-F083”, Rev. Date Aug. 8, 2011). Some of these methods, namely HPLC and GC/MS, can be expensive and labor-intensive, and are generally only performed in large or specialty labs having the appropriate equipment.
[0006] A need exists for other methods for determining the levels of anti-psychotic drugs, particularly methods that can be performed in a prescribing clinician's office (where the treatment for an individual patient can be adjusted accordingly in a much more timely manner) and in other medical settings lacking LC or GC/MS equipment or requiring rapid test results.

SUMMARY OF THE INVENTION

[0007] The present invention is directed to an isolated antibody or a binding fragment thereof, which binds to paliperidone and which: (i) is an antibody selected from the group consisting of: a) an isolated antibody or a fragment thereof comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7; b) an isolated antibody or a fragment thereof comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:8; c) an isolated antibody or a fragment thereof comprising a light chain variable region having the amino acid sequence of SEQ ID NO:3 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:4; or d) an isolated antibody or a fragment thereof comprising a light chain variable region having the amino acid sequence of SEQ ID NO:7 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:8; or (ii) competes for an epitope which is the same as an epitope bound by the antibody of (i).
[0008] The antibodies of the subject invention can be provided in assay kits and assay devices, with a presently preferred device being a lateral flow assay device which provides for point-of-care analysis.
[0009] The invention further provides a method of detecting paliperidone in a sample. The method comprises: (i) contacting a sample with an antibody according to the subject invention which is labeled with a detectable marker, wherein the labeled antibody and paliperidone present in the sample form a labeled complex; and (ii) detecting the labeled complex so as to detect paliperidone in the sample.
[0010] Further provided is a competitive immunoassay method for detecting paliperidone in a sample. The method comprises: (i) contacting a sample with an antibody according to the subject invention, and with paliperidone or a competitive binding partner of paliperidone, wherein one of the antibody and the paliperidone or competitive binding partner thereof is labeled with a detectable marker, and wherein sample paliperidone competes with the paliperidone or competitive binding partner thereof for binding to the antibody; and (ii) detecting the label so as to detect sample paliperidone.
[0011] Further objects, features and advantages of the present invention will be apparent to those skilled in the art from detailed consideration of the preferred embodiments that follow.

BRIEF DESCRIPTION OF THE DRAWINGS

[0012] FIGS. 1 and 2 show Competitive ELISA results generated with hybridoma 5-9;
[0013] FIG. 3 shows Competitive ELISA results generated with risperidone/paliperidone clone 2A5;
[0014] FIG. 4 shows the competitive immunoassay format used on a lateral flow assay device;
[0015] FIG. 5 shows a typical dose response curve generated with risperidone/paliperidone clone 5-9;
[0016] FIG. 6 shows the chip design of a lateral flow assay device according to the subject invention;
[0017] FIG. 7 shows a typical dose response curve for an aripiprazole positive control generated with antibody 5C7 and a labeled aripiprazole competitive binding partner;
[0018] FIG. 8 shows a typical dose response curve for an olanzapine positive control generated with antibody 4G9-1 and a labeled olanzapine competitive binding partner;
[0019] FIG. 9 shows a typical dose response curve for a quetiapine positive control generated with antibody 11 and a labeled quetiapine competitive binding partner;
[0020] FIG. 10 shows a typical dose response curve for a risperidone positive control generated with antibody 5-9 and a labeled risperidone competitive binding partner;
[0021] FIG. 11 shows a typical dose response curve for a sample containing aripiprazole generated with aripiprazole antibody 5C7 in the presence of labeled aripiprazole competitive binding partner, with no dose response curve for olanzapine, quetiapine, or risperidone in the presence of a labeled competitive binding partner for each;
[0022] FIG. 12 shows a typical dose response curve for a sample containing olanzapine generated with olanzapine antibody 4G9-1 in the presence of a labeled olanzapine competitive binding partner, with no dose response curve for aripiprazole, quetiapine, or risperidone in the presence of a labeled competitive binding partner for each;
[0023] FIG. 13 shows a typical dose response curve for a sample containing quetiapine generated with quetiapine antibody 11 in the presence of a labeled quetiapine competitive binding partner, with no dose response curve for aripiprazole, olanzapine, or risperidone in the presence of a labeled competitive binding partner for each;
[0024] FIG. 14 shows a typical dose response curve for a sample containing risperidone generated with risperidone antibody 5-9 in the presence of a labeled risperidone competitive binding partner, with no dose response curve for aripiprazole, olanzapine, or quetiapine in the presence of a labeled competitive binding partner for each;
[0025] FIG. 15 shows a typical dose response curve for a sample containing aripiprazole generated with aripiprazole antibody 5C7 in the presence of a labeled aripiprazole competitive binding partner, with no dose response curve for olanzapine, quetiapine, or risperidone in the presence of antibody and labeled competitive binding partner for each;
[0026] FIG. 16 shows a typical dose response curve for a sample containing olanzapine generated with olanzapine antibody 4G9-1 in the presence of a labeled olanzapine competitive binding partner, with no dose response curve for aripiprazole, quetiapine, or risperidone in the presence of antibody and labeled competitive binding partner for each;
[0027] FIG. 17 shows a typical dose response curve for a sample containing quetiapine generated with quetiapine antibody 11 in the presence of labeled quetiapine competitive binding partner, with no dose response curve for aripiprazole, olanzapine, or risperidone in the presence of antibody and labeled competitive binding partner for each;
[0028] FIG. 18 shows a typical dose response curve for a sample containing risperidone generated with risperidone antibody 5-9 in the presence of a labeled risperidone competitive binding partner, with no dose response curve for aripiprazole, olanzapine, or quetiapine in the presence of antibody and labeled competitive binding partner for each;
[0029] FIG. 19 shows a comparison of the aripiprazole dose response curve generated as a positive control to the aripiprazole dose response curve generated in the multiplex format;
[0030] FIG. 20 shows a comparison of the olanzapine dose response curve generated as a positive control to the olanzapine dose response curve generated in the multiplex format;
[0031] FIG. 21 shows a comparison of the quetiapine dose response curve generated as a positive control to the quetiapine dose response curve generated in the multiplex format; and
[0032] FIG. 22 shows a comparison of the risperidone dose response curve generated as a positive control to the risperidone dose response curve generated in the multiplex format.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[0033] The following terms are used to describe the sequence relationships between two or more polynucleotide or amino acid sequences: “reference sequence”, “comparison window”, “sequence identity”, “percentage of sequence identity”, “substantial identity”, “similarity”, and “homologous”. A “reference sequence” is a defined sequence used as a basis for a sequence comparison; a reference sequence may be a subset of a larger sequence, for example, a segment of a full length cDNA or gene sequence given in a sequence listing or may comprise a complete cDNA or gene sequence; a reference sequence may comprise a segment of a complete amino acid sequence encoding a protein as given in a sequence listing or may comprise a complete amino acid sequence encoding a protein. Generally, a reference sequence is at least 18 nucleotides or 6 amino acids in length, frequently at least 24 nucleotides or 8 amino acids in length, and often at least 48 nucleotides or 16 amino acids in length. Since two polynucleotide or amino acid sequences may each (1) comprise a sequence (i.e., a portion of the complete nucleotide or amino acid sequence) that is similar between the two molecules, and (2) may further comprise a sequence that is divergent between the two polynucleotide or amino acid sequences, sequence comparisons between two (or more) molecules are typically performed by comparing sequences of the two molecules over a “comparison window” to identify and compare local regions of sequence similarity. A “comparison window”, as used herein, refers to a conceptual segment of at least 18 contiguous nucleotide positions or 6 amino acids wherein the polynucleotide sequence or amino acid sequence may be compared to a reference sequence of at least 18 contiguous nucleotides or 6 amino acids and wherein the portion of the polynucleotide sequence or amino acid sequence in the comparison window may comprise additions, deletions, substitutions, and the like (i.e., gaps) of 20 percent or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith and Waterman, Adv. Appl. Math 2:482 (1981), by the homology alignment algorithm of Needlemen and Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0 (Genetics Computer Group, 575 Science Dr., Madison, Wis.), Geneworks or MacVector software packages), or by inspection, and the best alignment (i.e., resulting in the highest percentage of identity over the comparison window) generated by the various methods is selected.
[0034] The term “sequence identity” means that two polynucleotide or amino acid sequences are identical (i.e., on a nucleotide-by-nucleotide or amino acid residue-by-residue basis) over the comparison window. The term “percentage of sequence identity” is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, or U) or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term “substantial identity” as used herein denotes a characteristic of a polynucleotide or amino acid sequence, wherein the polynucleotide or amino acid sequence comprises a sequence that has at least 85 percent sequence identity, preferably at least 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison window of at least 18 nucleotide (6 amino acid) positions, frequently over a window of at least 24-48 nucleotide (8-16 amino acid) positions, wherein the percentage of sequence identity is calculated by comparing the reference sequence to the sequence which may include deletions or additions which total 20 percent or less of the reference sequence over the comparison window. The reference sequence may be a subset of a larger sequence. The term “similarity”, when used to describe a polypeptide, is determined by comparing the amino acid sequence and the conserved amino acid substitutions of one polypeptide to the sequence of a second polypeptide. The term “homologous”, when used to describe a polynucleotide, indicates that two polynucleotides, or designated sequences thereof, when optimally aligned and compared, are identical, with appropriate nucleotide insertions or deletions, in at least 70% of the nucleotides, usually from about 75% to 99%, and more preferably at least about 98% to 99% of the nucleotides.
[0035] A “label,” “detector molecule,” “reporter” or “detectable marker” as used herein is any molecule which produces, or can be induced to produce, a detectable signal. The label can be conjugated to an analyte, immunogen, antibody, or to another molecule such as a receptor or a molecule that can bind to a receptor such as a ligand, particularly a hapten or antibody. A label can be attached directly or indirectly by means of a linking or bridging moiety. Non-limiting examples of labels include radioactive isotopes (e.g., 125I), enzymes (e.g. β-galactosidase, peroxidase), enzyme fragments, enzyme substrates, enzyme inhibitors, coenzymes, catalysts, fluorophores (e.g., rhodamine, fluorescein isothiocyanate or FITC, or Dylight 649), dyes, chemiluminescers and luminescers (e.g., dioxetanes, luciferin), or sensitizers.
[0036] The invention provides an isolated antibody which binds to paliperidone. The invention further provides an assay kit and an assay device comprising the antibody. Further provided is a method of detecting paliperidone in a sample, including a competitive immunoassay method.
[0037] In one embodiment, the present invention is directed to an isolated antibody or a binding fragment thereof, which binds to paliperidone and which: (i) is an antibody selected from the group consisting of: a) an isolated antibody or a fragment thereof comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7; b) an isolated antibody or a fragment thereof comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:8; c) an isolated antibody or a fragment thereof comprising a light chain variable region having the amino acid sequence of SEQ ID NO:3 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:4; or d) an isolated antibody or a fragment thereof comprising a light chain variable region having the amino acid sequence of SEQ ID NO:7 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:8; or (ii) competes for an epitope which is the same as an epitope bound by the antibody of (i).
[0038] In a further embodiment, the present invention is directed to an isolated antibody or a binding fragment thereof, which binds to paliperidone and which comprises a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO:3 or SEQ ID NO:7.
[0039] In a further embodiment, the present invention is directed to an isolated antibody or a binding fragment thereof, which binds to paliperidone and which comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with SEQ ID NO:4 or SEQ ID NO:8.
[0040] Presently preferred embodiments of the antibody of the subject invention are: an antibody which comprises a light chain variable region having the amino acid sequence SEQ ID NO:3 and a heavy chain variable region having the amino acid sequence SEQ ID NO:4; and an antibody which comprises a light chain variable region having the amino acid sequence SEQ ID NO:7 and a heavy chain variable region having the amino acid sequence SEQ ID NO:8.
[0041] Additional presently preferred embodiments of the antibody of the subject invention are: 1) an antibody which comprises a light chain CDR1 sequence comprising amino acid residues 44 to 60 of SEQ ID NO:3, a light chain CDR2 sequence comprising amino acid residues 76 to 82 of SEQ ID NO:3, a light chain CDR3 sequence comprising amino acid residues 115 to 123 of SEQ ID NO:3, a heavy chain CDR1 sequence comprising amino acid residues 45 to 54 of SEQ ID NO:4, a heavy chain CDR2 sequence comprising amino acid residues 69 to 85 of SEQ ID NO:4, and a heavy chain CDR3 sequence comprising amino acid residues 118 to 122 of SEQ ID NO:4; and 2) an antibody which comprises a light chain CDR1 sequence comprising amino acid residues 44 to 60 of SEQ ID NO:7, a light chain CDR2 sequence comprising amino acid residues 76 to 82 of SEQ ID NO:7, a light chain CDR3 sequence comprising amino acid residues 115 to 123 of SEQ ID NO:7, a heavy chain CDR1 sequence comprising amino acid residues 45 to 54 of SEQ ID NO:8, a heavy chain CDR2 sequence comprising amino acid residues 69 to 85 of SEQ ID NO:8, and a heavy chain CDR3 sequence comprising amino acid residues 118 to 122 of SEQ ID NO:8.
[0042] Further details of the antibodies of the subject invention are provided in the section below entitled “Antibodies”.
[0043] The subject invention further provides an assay kit comprising the antibody, as well as an assay device comprising the antibody. Preferably, the assay device is a lateral flow assay device. Further details of the assay kits and assay devices are provided below in the section entitled “Assay Kits and Devices”.
[0044] The invention further provides a method of detecting paliperidone in a sample. The method comprises: (i) contacting a sample with an antibody according to the subject invention which is labeled with a detectable marker, wherein the labeled antibody and paliperidone present in the sample form a labeled complex; and (ii) detecting the labeled complex so as to detect paliperidone in the sample. Further details of the method of detecting paliperidone in accordance with the subject invention are provided in the section below entitled “Immunoassays”.
[0045] Further provided is a competitive immunoassay method for detecting paliperidone in a sample. The method comprises: (i) contacting a sample with an antibody according to the subject invention, and with paliperidone or a competitive binding partner of paliperidone, wherein one of the antibody and the paliperidone or competitive binding partner thereof is labeled with a detectable marker, and wherein sample paliperidone competes with the paliperidone or competitive binding partner thereof for binding to the antibody; and (ii) detecting the label so as to detect sample paliperidone. Further details of the competitive immunoassay method of detecting paliperidone in accordance with the subject invention are provided in the section below entitled “Immunoassays”.
[0046] In a preferred embodiment of the subject invention, the detection of paliperidone is accompanied by the detection of one or more analytes in addition to paliperidone. Preferably the one or more analytes are anti-psychotic drugs other than paliperidone, and more preferably the anti-psychotic drugs other than paliperidone are selected from the group consisting of: aripiprazole, risperidone, quetiapine, olanzapine, and metabolites thereof.
[0047] As discussed above, the antibodies of the subject invention can be used in assays to detect the presence and/or amount of the anti-psychotic drug in patient samples. Such detection permits therapeutic drug monitoring enabling all of the benefits thereof. Detection of levels of anti-psychotic drugs may be useful for many purposes, each of which represents another embodiment of the subject invention, including: determination of patient adherence or compliance with prescribed therapy; use as a decision tool to determine whether a patient should be converted from an oral anti-psychotic regimen to a long-acting injectable anti-psychotic regimen; use as a decision tool to determine if the dose level or dosing interval of oral or injectable anti-psychotics should be increased or decreased to ensure attainment or maintenance of efficacious or safe drug levels; use as an aid in the initiation of anti-psychotic drug therapy by providing evidence of the attainment of minimum pK levels; use to determine bioequivalence of anti-psychotic drug in multiple formulations or from multiple sources; use to assess the impact of polypharmacy and potential drug-drug interactions; and use as an indication that a patient should be excluded from or included in a clinical trial and as an aid in the subsequent monitoring of adherence to clinical trial medication requirements.

Antibodies

[0048] The present invention provides an isolated antibody which binds to paliperidone. The term “antibody” refers to a specific protein capable of binding an antigen or portion thereof (in accordance with this invention, capable of binding to an anti-psychotic drug or metabolite thereof). An antibody is produced in response to an immunogen which may have been introduced into a host, e.g., an animal or a human, by injection. The generic term “antibody” includes polyclonal antibodies, monoclonal antibodies, and antibody fragments.
[0049] “Antibody” or “antigen-binding antibody fragment” refers to an intact antibody, or a fragment thereof, that competes with the intact antibody for binding. Generally speaking, an antibody or antigen-binding antibody fragment, is said to specifically bind an antigen when the dissociation constant is less than or equal to 1 μM, preferably less than or equal to 100 nM and most preferably less than or equal to 10 nM. Binding can be measured by methods know to those skilled in the art, an example being the use of a BIAcore™ instrument.
[0050] Antibodies are made up of two heavy chains and two light chains. Each heavy chain has one variable domain or region (VH) followed by a constant domain or region (CH1), a hinge region, and two more constant domains or regions (CH2 and CH3). Each light chain has one variable domain or region (VL) and one constant domain or region (CL). The variable domains or regions of the heavy and light chains form the paratope of the antibody (a structure analogous to a lock), which is specific for a particular epitope (similarly analogous to a key), allowing the paratope and the epitope to bind together with precision. Within the variable domain, variable loops of β-strands, three each on the light and heavy chains, are responsible for binding to the antigen. These loops are referred to as the complementarity determining regions (CDRs, namely CDR1, CDR2, and CDR3).
[0051] Antibody fragments comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Binding fragments include Fab, Fab′, F(ab′)2, and Fv fragments; diabodies; minibodies; linear antibodies; single-chain antibody molecules (e.g., scFV); and multispecific antibodies formed from antibody fragments. An antibody other than a “bispecific” or “bifunctional” antibody is understood to have each of its binding sites identical.
[0052] As used herein, “epitope” includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. Two antibodies are said to “bind the same epitope” (“compete”) if one antibody is shown to compete with the second antibody in a competitive binding assay, by any of the methods well known to those skilled in the art (such as the BIAcore™ method referred to above). In reference to a hapten (such as paliperidone or other anti-psychotic drug), an antibody can be generated against the non-antigenic hapten molecule by conjugating the hapten to an immunogenic carrier. An antibody is then generated which recognizes an “epitope” defined by the hapten.
[0053] “Isolated” when used in the context of an antibody means altered “by the hand of man” from any natural state; i.e., that, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a naturally occurring antibody naturally present in a living animal in its natural state is not “isolated”, but the same antibody separated from the coexisting materials of its natural state is “isolated”, as the term is employed herein. Antibodies may occur in a composition, such as an immunoassay reagent, which are not naturally occurring compositions, and therein remain isolated antibodies within the meaning of that term as it is employed herein.
[0054] “Cross-reactivity” refers to the reaction of an antibody with an antigen that was not used to induce that antibody.
[0055] Preferably, the antibody of the subject invention will bind to the drug and any desired pharmacologically active metabolites. By altering the location of the attachment of an immunogenic carrier in a drug conjugate, selectivity and cross-reactivity with metabolites and/or related drugs can be engineered into the antibodies. For paliperidone (9-hydroxyrisperidone), cross-reactivity with risperidone or other risperidone metabolites such as 7-hydroxyrisperidone and N-dealkylrisperidone may or may not be desirable. An antibody that cross-reacts with risperidone and paliperidone may be desirable, which does not react with 7-hydroxyrisperidone or N-dealkylrisperidone, thus detecting risperidone and its major pharmacologically active metabolite paliperidone. Alternatively, it may be desirable to detect the pharmacologically active metabolites, risperidone and paliperidone, separately, while still not detecting the inactive metabolites, 7-hydroxyrisperidone and N-dealkylrisperidone. Antibodies may be generated that detect multiple ones of these drugs and/or metabolites, or antibodies may be generated that detect each separately (thus defining the antibody “specific binding” properties). An antibody specifically binds one or more compounds when its binding of the one or more compounds is equimolar or substantially equimolar.
[0056] The antibodies herein are described by the nucleotide and amino acid sequences of their variable domains. Each was generated by inoculating a host with a conjugate comprising an anti-psychotic drug conjugated to an immunogenic carrier. Having now provided the nucleotide and amino acid sequences thereof, the antibodies can be produced by the recombinant methods such as are described in U.S. Pat. No. 4,166,452.
[0057] Antibody fragments which contain specific binding sites for the anti-psychotic drug may also be generated. Such fragments include, but are not limited to, the F(ab′)2 fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab′)2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse et al., Science 256:1270-1281 (1989)). Fab, Fv and ScFv antibody fragments can all be expressed in and secreted from Escherichia coli, allowing for the production of large amounts of these fragments. Alternatively, Fab′-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab′)2 fragments (Carter et al., BioTechnology 10:163-167 (1992)). Other techniques for the production of antibody fragments are known to those skilled in the art. Single chain Fv fragments (scFv) are also envisioned (see U.S. Pat. Nos. 5,761,894 and 5,587,458). Fv and sFv fragments are the only species with intact combining sites that are devoid of constant regions; thus, they are likely to show reduced non-specific binding. The antibody fragment may also be a “linear antibody” e.g., as described in U.S. Pat. No. 5,642,870, for example. Such linear antibody fragments may be monospecific or bispecific.

Assay Kits and Devices

[0058] An assay kit (also referred to as a reagent kit) can also be provided comprising an antibody as described above. A representative reagent kit may comprise an antibody that binds to the anti-psychotic drug, paliperidone, a complex comprising an analog of an anti-psychotic drug or a derivative thereof coupled to a labeling moiety, and may optionally also comprise one or more calibrators comprising a known amount of an anti-psychotic drug or a related standard.
[0059] The phrase “assay kit” refers to an assembly of materials and reagents that is used in performing an assay. The reagents can be provided in packaged combination in the same or in separate containers, depending on their cross-reactivities and stabilities, and in liquid or in lyophilized form. The amounts and proportions of reagents provided in the kit can be selected so as to provide optimum results for a particular application. An assay kit embodying features of the present invention comprises antibodies which bind paliperidone. The kit may further comprise competitive binding partners of paliperidone and calibration and control materials.
[0060] The phrase “calibration and control material” refers to any standard or reference material containing a known amount of an analyte. A sample suspected of containing an analyte and the corresponding calibration material are assayed under similar conditions. The concentration of analyte is calculated by comparing the results obtained for the unknown specimen with the results obtained for the standard. This is commonly done by constructing a calibration curve.
[0061] Antibodies embodying features of the present invention can be included in a kit, container, pack, or dispenser together with instructions for their utilization. When the antibodies are supplied in a kit, the different components of the immunoassay may be packaged in separate containers and admixed prior to use. Such packaging of the components separately may permit long-term storage without substantially diminishing the functioning of the active components. Furthermore, reagents can be packaged under inert environments, e.g., under a positive pressure of nitrogen gas, argon gas, or the like, which is especially preferred for reagents that are sensitive to air and/or moisture.
[0062] Reagents included in kits embodying features of the present invention can be supplied in all manner of containers such that the activities of the different components are substantially preserved while the components themselves are not substantially adsorbed or altered by the materials of the container. Suitable containers include, but are not limited to, ampules, bottles, test tubes, vials, flasks, syringes, envelopes, e.g., foil-lined, and the like. The containers may be comprised of any suitable material including, but not limited to, glass, organic polymers, e.g., polycarbonate, polystyrene, polyethylene, etc., ceramic, metal, e.g., aluminum, metal alloys, e.g., steel, cork, and the like. In addition, the containers may comprise one or more sterile access ports, e.g., for access via a needle, such as may be provided by a septum. Preferred materials for septa include rubber and polytetrafluoroethylene of the type sold under the trade name TEFLON by DuPont (Wilmington, Del.). In addition, the containers may comprise two or more compartments separated by partitions or membranes that can be removed to allow mixing of the components.
[0063] Reagent kits embodying features of the present invention may also be supplied with instructional materials. Instructions may be printed, e.g., on paper and/or supplied in an electronically-readable medium. Alternatively, instructions may be provided by directing a user to an internet website, e.g., specified by the manufacturer or distributor of the kit and/or via electronic mail.
[0064] The antibody may also be provided as part of an assay device. Such assay devices include lateral flow assay devices. A common type of disposable lateral flow assay device includes a zone or area for receiving the liquid sample, a conjugate zone, and a reaction zone. These assay devices are commonly known as lateral flow test strips. They employ a porous material, e.g., nitrocellulose, defining a path for fluid flow capable of supporting capillary flow. Examples include those shown in U.S. Pat. Nos. 5,559,041, 5,714,389, 5,120,643, and 6,228,660 all of which are incorporated herein by reference in their entireties.
[0065] Another type of assay device is a non-porous assay device having projections to induce capillary flow. Examples of such assay devices include the open lateral flow device as disclosed in PCT International Publication Nos. WO 2003/103835, WO 2005/089082, WO 2005/118139, and WO 2006/137785, all of which are incorporated herein by reference in their entireties.
[0066] In a non-porous assay device, the assay device generally has at least one sample addition zone, at least one conjugate zone, at least one reaction zone, and at least one wicking zone. The zones form a flow path by which sample flows from the sample addition zone to the wicking zone. Also included are capture elements, such as antibodies, in the reaction zone, capable of binding to the analyte, optionally deposited on the device (such as by coating); and a labeled conjugate material also capable of participating in reactions that will enable determination of the concentration of the analyte, deposited on the device in the conjugate zone, wherein the labeled conjugate material carries a label for detection in the reaction zone. The conjugate material is dissolved as the sample flows through the conjugate zone forming a conjugate plume of dissolved labeled conjugate material and sample that flows downstream to the reaction zone. As the conjugate plume flows into the reaction zone, the conjugated material will be captured by the capture elements such as via a complex of conjugated material and analyte (as in a “sandwich” assay) or directly (as in a “competitive” assay). Unbound dissolved conjugate material will be swept past the reaction zone into the at least one wicking zone. Such devices can include projections or micropillars in the flow path.
[0067] An instrument such as that disclosed in US Patent Publication Nos. US20060289787A1 and US 20070231883A1, and U.S. Pat. Nos. 7,416,700 and 6,139,800, all of which are incorporated herein by reference in their entireties, is able to detect the bound conjugated material in the reaction zone. Common labels include fluorescent dyes that can be detected by instruments which excite the fluorescent dyes and incorporate a detector capable of detecting the fluorescent dyes.

Immunoassays

[0068] The antibodies thus produced can be used in immunoassays to recognize/bind to the anti-psychotic drug, thereby detecting the presence and/or amount of the drug in a patient sample. Preferably, the assay format is a competitive immunoassay format. Such an assay format and other assays are described, among other places, in Hampton et al. (Serological Methods, A Laboratory Manual, APS Press, St. Paul, Minn. 1990) and Maddox et al. (J. Exp. Med. 158:12111, 1983).
[0069] The term “analyte” refers to any substance or group of substances, the presence or amount of which is to be determined. Representative anti-psychotic drug analytes include, but are not limited to, risperidone, paliperidone, olanzapine, aripiprazole, and quetiapine.
[0070] The term “competitive binding partner” refers to a substance or group of substances, such as may be employed in a competitive immunoassay, which behave similarly to an analyte with respect to binding affinity to an antibody. Representative competitive binding partners include, but are not limited to, anti-psychotic drug derivatives and the like.
[0071] The term “detecting” when used with an analyte refers to any quantitative, semi-quantitative, or qualitative method as well as to all other methods for determining an analyte in general, and an anti-psychotic drug in particular. For example, a method that merely detects the presence or absence of an anti-psychotic drug in a sample lies within the scope of the present invention, as do methods that provide data as to the amount or concentration of the anti-psychotic drug in the sample. The terms “detecting”, “determining”, “identifying”, and the like are used synonymously herein, and all lie within the scope of the present invention.
[0072] A preferred embodiment of the subject invention is a competitive immunoassay wherein antibodies which bind the anti-psychotic drug, or the drug or competitive binding partner thereof, are attached to a solid support (such as the reaction zone in a lateral flow assay device) and labeled drug or competitive binding partner thereof, or labeled antibody, respectively, and a sample derived from the host are passed over the solid support and the amount of label detected attached to the solid support can be correlated to a quantity of drug in the sample.
[0073] Any sample that is suspected of containing an analyte, e.g., an anti-psychotic drug, can be analyzed in accordance with the methods of the presently preferred embodiments. The sample can be pretreated if desired and can be prepared in any convenient medium that does not interfere with the assay. Preferably, the sample comprises an aqueous medium such as a body fluid from a host, most preferably plasma or serum.
[0074] It is to be understood that all manner of immunoassays employing antibodies are contemplated for use in accordance with the presently preferred embodiments, including assays in which antibodies are bound to solid phases and assays in which antibodies are in liquid media. Methods of immunoassays that can be used to detect analytes using antibodies embodying features of the present invention include, but are not limited to, competitive (reagent limited) assays wherein labeled analyte (analyte analog) and analyte in a sample compete for antibodies and single-site immunometric assays wherein the antibody is labeled; and the like.
[0075] All examples were carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. Routine molecular biology techniques of the following examples can be carried out as described in standard laboratory manuals, such as Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).
[0076] Copending applications entitled “Haptens of Aripiprazole” (U.S. Provisional Patent Application No. 61/691,450, filed Aug. 21, 2012, and US 20140163206, filed Aug. 20, 2013, “Haptens of Olanzapine” (U.S. Provisional Patent Application No. 61/691,454, filed Aug. 21, 2012, and U.S. 20140213766, filed Aug. 20, 2013, “Haptens of Paliperidone” (U.S. Provisional Patent Application No. 61/691,459, filed Aug. 21, 2012, and US 20140213767, filed Aug. 20, 2013, “Haptens of Quetiapine” (U.S. Provisional Patent Application No. 61/691,462, filed Aug. 21, 2012, and US 20140221616, filed Aug. 20, 2013, “Haptens of Risperidone and Paliperidone” (U.S. Provisional Patent Application No. 61/691,469, filed Aug. 21, 2012, and US 20140155585, Aug. 20, 2013, “Antibodies to Aripiprazole Haptens and Use Thereof” (US Provisional Patent Application No. 61/691,544, filed Aug. 21, 2012, and US 20140057299, filed Aug. 20, 2013, “Antibodies to Olanzapine Haptens and Use Thereof” (U.S. Provisional Patent Application No. 61/691,572, filed Aug. 21, 2012, US 20140057303, filed Aug. 20, 2013, “Antibodies to Paliperidone Haptens and Use Thereof” (US Provisional Patent Application No. 61/691,634, filed Aug. 21, 2012, and U.S. 20140057297, filed Aug. 20, 2013, “Antibodies to Quetiapine Haptens and Use Thereof” (U.S. Provisional Patent Application No. 61/691,598, filed Aug. 21, 2012, and US 20140057305, filed Aug. 20, 2013, “Antibodies to Risperidone Haptens and Use Thereof” (U.S. Provisional Patent Application No. 61/691,615, filed Aug. 21, 2012, and US 20140057301, filed Aug. 20, 2013, “Antibodies to Aripiprazole and Use Thereof” (U.S. Provisional Patent Application No. 61/691,522, filed Aug. 21, 2012, and US 20140057300, filed Aug. 20, 2013, “Antibodies to Olanzapine and Use Thereof” (U.S. Provisional Patent Application No. 61/691,645, filed Aug. 21, 2012, and US 20140057304, filed Aug. 20, 2013, “Antibodies to Quetiapine and Use Thereof” (U.S. Provisional Patent Application No. 61/691,659, filed Aug. 21, 2012, and US 20140057306, filed Aug. 20, 2013, as well as priority applications “Antibodies to Risperidone and Use Thereof” (U.S. Provisional Patent Application No. 61/691,675, filed Aug. 21, 2012, and “Antibodies to Risperidone and Use Thereof” (U.S. Provisional Patent Application No. 61/790,880, filed Mar. 15, 2013, are all incorporated herein by reference in their entireties.

EXAMPLE 1

Antibodies to Aripiprazole

[0077] Antibody 17.3 Clone 3D7
[0078] The hybridoma designated 17.3 clone 3D7 secretes a monoclonal antibody (mAb) specific for aripiprazole. The antibody is designated 17.3 clone 3D7. The nucleotide sequence of mAb 17.3 clone 3D7's light chain variable region (VL) is designated SEQ ID NO:41 and that of the heavy chain variable region (VH) is designated SEQ ID NO:42. Within mAb 17.3 clone 3D7's VL, nucleotides 136-165 of SEQ ID NO:41 represent the first complementarity determining region (CDR1); nucleotides 211-231 of SEQ ID NO:41 represent the second complementarity determining region (CDR2); and nucleotides 328-354 of SEQ ID NO:41 represent the third complementarity determining region (CDR3). Within mAb 17.3 clone 3D7's VH, nucleotides 133-162 of SEQ ID NO:42 represent the first complementarity determining region (CDR1); nucleotides 205-255 of SEQ ID NO:42 represent the second complementarity determining region (CDR2); and nucleotides 352-375 of SEQ ID NO:42 represent the third complementarity determining region (CDR3).
[0079] The corresponding predicted amino acid sequences of mAb 17.3 clone 3D7's variable chain regions were also determined, and are designated SEQ ID NO:43 (light chain) and SEQ ID NO:44 (heavy chain). Within mAb 17.3 clone 3D7's VL, amino acid residues 46-55 of SEQ ID NO:43 represent the first complementarity determining region (CDR1); amino acid residues 71-77 of SEQ ID NO:43 represent the second complementarity determining region (CDR2); and amino acid residues 110-118 of SEQ ID NO:43 represent the third complementarity determining region (CDR3). Within mAb 17.3 clone 3D7's VH, amino acid residues 45-54 of SEQ ID NO:44 represent the first complementarity determining region (CDR1); amino acid residues 69-85 of SEQ ID NO:44 represent the second complementarity determining region (CDR2); and amino acid residues 118-125 of SEQ ID NO:44 represent the third complementarity determining region (CDR3).
[0080] Antibody 17.3 Clone 5C7 (First)
[0081] The hybridoma designated 17.3 clone 5C7 (first) secretes a monoclonal antibody (mAb) specific for aripiprazole. The antibody is designated 17.3 clone 5C7 (first). The nucleotide sequence of mAb 17.3 clone 5C7 (first)'s light chain variable region (VL) is designated SEQ ID NO:45 and that of the heavy chain variable region (VH) is designated SEQ ID NO:46. Within mAb 17.3 clone 5C7 (first)'s VL, nucleotides 130-162 of SEQ ID NO:45 represent the first complementarity determining region (CDR1); nucleotides 208-228 of SEQ ID NO:45 represent the second complementarity determining region (CDR2); and nucleotides 325-351 of SEQ ID NO:45 represent the third complementarity determining region (CDR3). Within mAb 17.3 clone 5C7 (first)'s VH, nucleotides 133-162 of SEQ ID NO:46 represent the first complementarity determining region (CDR1); nucleotides 205-255 of SEQ ID NO:46 represent the second complementarity determining region (CDR2); and nucleotides 352-378 of SEQ ID NO:46 represent the third complementarity determining region (CDR3).
[0082] The corresponding predicted amino acid sequences of mAb 17.3 clone 5C7 (first)'s variable chain regions were also determined, and are designated SEQ ID NO:47 (light chain) and SEQ ID NO:48 (heavy chain). Within mAb 17.3 clone 5C7 (first)'s VL, amino acid residues 44-54 of SEQ ID NO:47 represent the first complementarity determining region (CDR1); amino acid residues 70-76 of SEQ ID NO:47 represent the second complementarity determining region (CDR2); and amino acid residues 109-117 of SEQ ID NO:47 represent the third complementarity determining region (CDR3). Within mAb 17.3 clone 5C7 (first)'s VH, amino acid residues 45-54 of SEQ ID NO:48 represent the first complementarity determining region (CDR1); amino acid residues 69-85 of SEQ ID NO:48 represent the second complementarity determining region (CDR2); and amino acid residues 118-126 of SEQ ID NO:48 represent the third complementarity determining region (CDR3).
[0083] Antibody 17.3 Clone 5C7 (Second)
[0084] The hybridoma designated 17.3 clone 5C7 (second) secretes a monoclonal antibody (mAb) specific for aripiprazole. The antibody is designated 17.3 clone 5C7 (second). The nucleotide sequence of mAb 17.3 clone 5C7 (second)'s light chain variable region (VL) is designated SEQ ID NO:49 and that of the heavy chain variable region (VH) is designated SEQ ID NO:50. Within mAb 17.3 clone 5C7 (second)'s VL, nucleotides 130-174 of SEQ ID NO:49 represent the first complementarity determining region (CDR1); nucleotides 220-240 of SEQ ID NO:49 represent the second complementarity determining region (CDR2); and nucleotides 337-363 of SEQ ID NO:49 represent the third complementarity determining region (CDR3). Within mAb 17.3 clone 5C7 (second)'s VH, nucleotides 133-162 of SEQ ID NO:50 represent the first complementarity determining region (CDR1); nucleotides 205-255 of SEQ ID NO:50 represent the second complementarity determining region (CDR2); and nucleotides 352-390 of SEQ ID NO:50 represent the third complementarity determining region (CDR3).
[0085] The corresponding predicted amino acid sequences of mAb 17.3 clone 5C7 (second)'s variable chain regions were also determined, and are designated SEQ ID NO:51 (light chain) and SEQ ID NO:52 (heavy chain). Within mAb 17.3 clone 5C7 (second)'s VL, amino acid residues 44-58 of SEQ ID NO:51 represent the first complementarity determining region (CDR1); amino acid residues 74-80 of SEQ ID NO:51 represent the second complementarity determining region (CDR2); and amino acid residues 113-121 of SEQ ID NO:51 represent the third complementarity determining region (CDR3). Within mAb 17.3 clone 5C7 (second)'s VH, amino acid residues 45-54 of SEQ ID NO:52 represent the first complementarity determining region (CDR1); amino acid residues 69-85 of SEQ ID NO:52 represent the second complementarity determining region (CDR2); and amino acid residues 118-130 of SEQ ID NO:52 represent the third complementarity determining region (CDR3).
[0086] Antibody 17.3 Clone 5C7 (Third)
[0087] The hybridoma designated 17.3 clone 5C7 (third) secretes a monoclonal antibody (mAb) specific for aripiprazole. The antibody is designated 17.3 clone 5C7 (third). The nucleotide sequence of mAb 17.3 clone 5C7 (third)'s light chain variable region (VL) is designated SEQ ID NO:53 and that of the heavy chain variable region (VH) is designated SEQ ID NO:54. Within mAb 17.3 clone 5C7 (third)'s VL, nucleotides 130-162 of SEQ ID NO:53 represent the first complementarity determining region (CDR1); nucleotides 208-228 of SEQ ID NO:53 represent the second complementarity determining region (CDR2); and nucleotides 325-351 of SEQ ID NO:53 represent the third complementarity determining region (CDR3). Within mAb 17.3 clone 5C7 (third)'s VH, nucleotides 133-162 of SEQ ID NO:54 represent the first complementarity determining region (CDR1); nucleotides 205-255 of SEQ ID NO:54 represent the second complementarity determining region (CDR2); and nucleotides 352-366 of SEQ ID NO:54 represent the third complementarity determining region (CDR3).
[0088] The corresponding predicted amino acid sequences of mAb 17.3 clone 5C7 (third)'s variable chain regions were also determined, and are designated SEQ ID NO:55 (light chain) and SEQ ID NO:56 (heavy chain). Within mAb 17.3 clone 5C7 (third)'s VL, amino acid residues 44-54 of SEQ ID NO:55 represent the first complementarity determining region (CDR1); amino acid residues 70-76 of SEQ ID NO:55 represent the second complementarity determining region (CDR2); and amino acid residues 109-117 of SEQ ID NO:55 represent the third complementarity determining region (CDR3). Within mAb 17.3 clone 5C7 (third)'s VH, amino acid residues 45-54 of SEQ ID NO:56 represent the first complementarity determining region (CDR1); amino acid residues 69-85 of SEQ ID NO:56 represent the second complementarity determining region (CDR2); and amino acid residues 118-122 of SEQ ID NO:56 represent the third complementarity determining region (CDR3).

EXAMPLE 2

Antibodies to Olanzapine

[0089] Antibody 11.1 Clone 35
[0090] The hybridoma designated 11.1 clone 35 secretes a monoclonal antibody (mAb) specific for olanzapine. The antibody is designated 11.1 clone 35. The nucleotide sequence of mAb 11.1 clone 35's light chain variable region (VL) is designated SEQ ID NO:9 and that of the heavy chain variable region (VH) is designated SEQ ID NO:10. Within mAb 11.1 clone 35's VL, nucleotides 130-162 of SEQ ID NO:9 represent the first complementarity determining region (CDR1); nucleotides 208-228 of SEQ ID NO:9 represent the second complementarity determining region (CDR2); and nucleotides 325-351 of SEQ ID NO:9 represent the third complementarity determining region (CDR3). Within mAb 11.1 clone 35's VH, nucleotides 133-162 of SEQ ID NO:10 represent the first complementarity determining region (CDR1); nucleotides 205-255 of SEQ ID NO:10 represent the second complementarity determining region (CDR2); and nucleotides 352-366 of SEQ ID NO:10 represent the third complementarity determining region (CDR3).
[0091] The corresponding predicted amino acid sequences of mAb 11.1 clone 35's variable chain regions were also determined, and are designated SEQ ID NO:11 (light chain) and SEQ ID NO:12 (heavy chain). Within mAb 11.1 clone 35's VL, amino acid residues 44-54 of SEQ ID NO:11 represent the first complementarity determining region (CDR1); amino acid residues 70-76 of SEQ ID NO:11 represent the second complementarity determining region (CDR2); and amino acid residues 109-117 of SEQ ID NO:11 represent the third complementarity determining region (CDR3). Within mAb 11.1 clone 35's VH, amino acid residues 45-54 of SEQ ID NO:12 represent the first complementarity determining region (CDR1); amino acid residues 69-85 of SEQ ID NO:12 represent the second complementarity determining region (CDR2); and amino acid residues 118-122 of SEQ ID NO:12 represent the third complementarity determining region (CDR3).
[0092] Antibody 11.1 Clone 61
[0093] The hybridoma designated 11.1 clone 61 secretes a monoclonal antibody (mAb) specific for olanzapine. The antibody is designated 11.1 clone 61. The nucleotide sequence of mAb 11.1 clone 61's light chain variable region (VL) is designated SEQ ID NO:13 and that of the heavy chain variable region (VH) is designated SEQ ID NO:14. Within mAb 11.1 clone 61's VL, nucleotides 130-162 of SEQ ID NO:13 represent the first complementarity determining region (CDR1); nucleotides 208-228 of SEQ ID NO:13 represent the second complementarity determining region (CDR2); and nucleotides 325-351 of SEQ ID NO:13 represent the third complementarity determining region (CDR3). Within mAb 11.1 clone 61's VH, nucleotides 133-162 of SEQ ID NO:14 represent the first complementarity determining region (CDR1); nucleotides 205-255 of SEQ ID NO:14 represent the second complementarity determining region (CDR2); and nucleotides 352-366 of SEQ ID NO:14 represent the third complementarity determining region (CDR3).
[0094] The corresponding predicted amino acid sequences of mAb 11.1 clone 61's variable chain regions were also determined, and are designated SEQ ID NO:15 (light chain) and SEQ ID NO:16 (heavy chain). Within mAb 11.1 clone 61's VL, amino acid residues 44-54 of SEQ ID NO:15 represent the first complementarity determining region (CDR1); amino acid residues 70-76 of SEQ ID NO:15 represent the second complementarity determining region (CDR2); and amino acid residues 109-117 of SEQ ID NO:15 represent the third complementarity determining region (CDR3). Within mAb 11.1 clone 61's VH, amino acid residues 45-54 of SEQ ID NO:16 represent the first complementarity determining region (CDR1); amino acid residues 69-85 of SEQ ID NO:16 represent the second complementarity determining region (CDR2); and amino acid residues 118-122 of SEQ ID NO:16 represent the third complementarity determining region (CDR3).
[0095] Antibody 15.5 Clone 3F11 (First)
[0096] The hybridoma designated 15.5 clone 3F11 (first) secretes a monoclonal antibody (mAb) specific for olanzapine. The antibody is designated 15.5 clone 3F11 (first). The nucleotide sequence of mAb 15.5 clone 3F11 (first)'s light chain variable region (VL) is designated SEQ ID NO:29 and that of the heavy chain variable region (VH) is designated SEQ ID NO:30. Within mAb 15.5 clone 3F11 (first)'s VL, nucleotides 130-162 of SEQ ID NO:29 represent the first complementarity determining region (CDR1); nucleotides 208-228 of SEQ ID NO:29 represent the second complementarity determining region (CDR2); and nucleotides 325-351 of SEQ ID NO:29 represent the third complementarity determining region (CDR3). Within mAb 15.5 clone 3F11 (first)'s VH, nucleotides 130-162 of SEQ ID NO:30 represent the first complementarity determining region (CDR1); nucleotides 205-252 of SEQ ID NO:30 represent the second complementarity determining region (CDR2); and nucleotides 355-381 of SEQ ID NO:30 represent the third complementarity determining region (CDR3).
[0097] The corresponding predicted amino acid sequences of mAb 15.5 clone 3F11 (first)'s variable chain regions were also determined, and are designated SEQ ID NO:31 (light chain) and SEQ ID NO:32 (heavy chain). Within mAb 15.5 clone 3F11 (first)'s VL, amino acid residues 44-54 of SEQ ID NO:31 represent the first complementarity determining region (CDR1); amino acid residues 70-76 of SEQ ID NO:31 represent the second complementarity determining region (CDR2); and amino acid residues 109-117 of SEQ ID NO:31 represent the third complementarity determining region (CDR3). Within mAb 15.5 clone 3F11 (first)'s VH, amino acid residues 44-54 of SEQ ID NO:32 represent the first complementarity determining region (CDR1); amino acid residues 69-84 of SEQ ID NO:32 represent the second complementarity determining region (CDR2); and amino acid residues 119-127 of SEQ ID NO:32 represent the third complementarity determining region (CDR3).
[0098] Antibody 15.5 Clone 3F11 (Second)
[0099] The hybridoma designated 15.5 clone 3F11 (second) secretes a monoclonal antibody (mAb) specific for olanzapine. The antibody is designated 15.5 clone 3F11 (second). The nucleotide sequence of mAb 15.5 clone 3F11 (second)'s light chain variable region (VL) is designated SEQ ID NO:33 and that of the heavy chain variable region (VH) is designated SEQ ID NO:34. Within mAb 15.5 clone 3F11 (second)'s VL, nucleotides 130-162 of SEQ ID NO:33 represent the first complementarity determining region (CDR1); nucleotides 208-228 of SEQ ID NO:33 represent the second complementarity determining region (CDR2); and nucleotides 325-351 of SEQ ID NO:33 represent the third complementarity determining region (CDR3). Within mAb 15.5 clone 3F11 (second)'s VH, nucleotides 133-162 of SEQ ID NO:34 represent the first complementarity determining region (CDR1); nucleotides 205-261 of SEQ ID NO:34 represent the second complementarity determining region (CDR2); and nucleotides 358-381 of SEQ ID NO:34 represent the third complementarity determining region (CDR3).
[0100] The corresponding predicted amino acid sequences of mAb 15.5 clone 3F11 (second)'s variable chain regions were also determined, and are designated SEQ ID NO:35 (light chain) and SEQ ID NO:36 (heavy chain). Within mAb 15.5 clone 3F11 (second)'s VL, amino acid residues 44-54 of SEQ ID NO:35 represent the first complementarity determining region (CDR1); amino acid residues 70-76 of SEQ ID NO:35 represent the second complementarity determining region (CDR2); and amino acid residues 109-117 of SEQ ID NO:35 represent the third complementarity determining region (CDR3). Within mAb 15.5 clone 3F11 (second)'s VH, amino acid residues 45-54 of SEQ ID NO:36 represent the first complementarity determining region (CDR1); amino acid residues 69-87 of SEQ ID NO:36 represent the second complementarity determining region (CDR2); and amino acid residues 120-127 of SEQ ID NO:36 represent the third complementarity determining region (CDR3).
[0101] Antibody 15.5 Sub-Clone 4G9-1
[0102] The hybridoma designated 15.5 sub-clone 4G9-1 secretes a monoclonal antibody (mAb) specific for olanzapine. The antibody is designated 15.5 sub-clone 4G9-1. The nucleotide sequence of mAb 15.5 sub-clone 4G9-1's light chain variable region (VL) is designated SEQ ID NO:37 and that of the heavy chain variable region (VH) is designated SEQ ID NO:38. Within mAb 15.5 sub-clone 4G9-1's VL, nucleotides 130-162 of SEQ ID NO:37 represent the first complementarity determining region (CDR1); nucleotides 208-228 of SEQ ID NO:37 represent the second complementarity determining region (CDR2); and nucleotides 325-351 of SEQ ID NO:37 represent the third complementarity determining region (CDR3). Within mAb 15.5 sub-clone 4G9-1's VH, nucleotides 130-162 of SEQ ID NO:38 represent the first complementarity determining region (CDR1); nucleotides 205-252 of SEQ ID NO:38 represent the second complementarity determining region (CDR2); and nucleotides 358-381 of SEQ ID NO:38 represent the third complementarity determining region (CDR3).
[0103] The corresponding predicted amino acid sequences of mAb 15.5 sub-clone 4G9-1's variable chain regions were also determined, and are designated SEQ ID NO:39 (light chain) and SEQ ID NO:40 (heavy chain). Within mAb 15.5 sub-clone 4G9-1's VL, amino acid residues 44-54 of SEQ ID NO:39 represent the first complementarity determining region (CDR1); amino acid residues 70-76 of SEQ ID NO:39 represent the second complementarity determining region (CDR2); and amino acid residues 109-117 of SEQ ID NO:39 represent the third complementarity determining region (CDR3). Within mAb 15.5 sub-clone 4G9-1's VH, amino acid residues 44-54 of SEQ ID NO:40 represent the first complementarity determining region (CDR1); amino acid residues 69-84 of SEQ ID NO:40 represent the second complementarity determining region (CDR2); and amino acid residues 120-127 of SEQ ID NO:40 represent the third complementarity determining region (CDR3).

EXAMPLE 3

Antibodies to Quetiapine

[0104] Antibody 13.2 Sub-Clone 89-3 (First)
[0105] The hybridoma designated 13.2 sub-clone 89-3 (first) secretes a monoclonal antibody (mAb) specific for quetiapine. The antibody is designated 13.2 sub-clone 89-3 (first). The nucleotide sequence of mAb 13.2 sub-clone 89-3 (first)'s light chain variable region (VL) is designated SEQ ID NO:17 and that of the heavy chain variable region (VH) is designated SEQ ID NO:18. Within mAb 13.2 sub-clone 89-3 (first)'s VL, nucleotides 127-174 of SEQ ID NO:17 represent the first complementarity determining region (CDR1); nucleotides 220-240 of SEQ ID NO:17 represent the second complementarity determining region (CDR2); and nucleotides 337-363 of SEQ ID NO:17 represent the third complementarity determining region (CDR3). Within mAb 13.2 sub-clone 89-3 (first)'s VH, nucleotides 133-162 of SEQ ID NO:18 represent the first complementarity determining region (CDR1); nucleotides 205-255 of SEQ ID NO:18 represent the second complementarity determining region (CDR2); and nucleotides 352-387 of SEQ ID NO:18 represent the third complementarity determining region (CDR3).
[0106] The corresponding predicted amino acid sequences of mAb 13.2 sub-clone 89-3 (first)'s variable chain regions were also determined, and are designated SEQ ID NO:19 (light chain) and SEQ ID NO:20 (heavy chain). Within mAb 13.2 sub-clone 89-3 (first)'s VL, amino acid residues 43-58 of SEQ ID NO:19 represent the first complementarity determining region (CDR1); amino acid residues 74-80 of SEQ ID NO:19 represent the second complementarity determining region (CDR2); and amino acid residues 113-121 of SEQ ID NO:19 represent the third complementarity determining region (CDR3). Within mAb 13.2 sub-clone 89-3 (first)'s VH, amino acid residues 45-54 of SEQ ID NO:20 represent the first complementarity determining region (CDR1); amino acid residues 69-85 of SEQ ID NO:20 represent the second complementarity determining region (CDR2); and amino acid residues 118-129 of SEQ ID NO:20 represent the third complementarity determining region (CDR3).
[0107] Antibody 13.2 Sub-Clone 89-3 (Second)
[0108] The hybridoma designated 13.2 sub-clone 89-3 (second) secretes a monoclonal antibody (mAb) specific for quetiapine. The antibody is designated 13.2 sub-clone 89-3 (second). The nucleotide sequence of mAb 13.2 sub-clone 89-3 (second)'s light chain variable region (VL) is designated SEQ ID NO:21 and that of the heavy chain variable region (VH) is designated SEQ ID NO:22. Within mAb 13.2 sub-clone 89-3 (second)'s VL, nucleotides 127-174 of SEQ ID NO:21 represent the first complementarity determining region (CDR1); nucleotides 220-240 of SEQ ID NO:21 represent the second complementarity determining region (CDR2); and nucleotides 337-363 of SEQ ID NO:21 represent the third complementarity determining region (CDR3). Within mAb 13.2 sub-clone 89-3 (second)'s VH, nucleotides 133-162 of SEQ ID NO:22 represent the first complementarity determining region (CDR1); nucleotides 205-255 of SEQ ID NO:22 represent the second complementarity determining region (CDR2); and nucleotides 367-387 of SEQ ID NO:22 represent the third complementarity determining region (CDR3).
[0109] The corresponding predicted amino acid sequences of mAb 13.2 sub-clone 89-3 (second)'s variable chain regions were also determined, and are designated SEQ ID NO:23 (light chain) and SEQ ID NO:24 (heavy chain). Within mAb 13.2 sub-clone 89-3 (second)'s VL, amino acid residues 43-58 of SEQ ID NO:23 represent the first complementarity determining region (CDR1); amino acid residues 74-80 of SEQ ID NO:23 represent the second complementarity determining region (CDR2); and amino acid residues 113-121 of SEQ ID NO:23 represent the third complementarity determining region (CDR3). Within mAb 13.2 sub-clone 89-3 (second)'s VH, amino acid residues 45-54 of SEQ ID NO:24 represent the first complementarity determining region (CDR1); amino acid residues 69-85 of SEQ ID NO:24 represent the second complementarity determining region (CDR2); and amino acid residues 123-129 of SEQ ID NO:24 represent the third complementarity determining region (CDR3).
[0110] Antibody 13.2 Sub-Clone 89-5
[0111] The hybridoma designated 13.2 sub-clone 89-5 secretes a monoclonal antibody (mAb) specific for quetiapine. The antibody is designated 13.2 sub-clone 89-5. The nucleotide sequence of mAb 13.2 sub-clone 89-5's light chain variable region (VL) is designated SEQ ID NO:25 and that of the heavy chain variable region (VH) is designated SEQ ID NO:26. Within mAb 13.2 sub-clone 89-5's VL, nucleotides 127-174 of SEQ ID NO:25 represent the first complementarity determining region (CDR1); nucleotides 220-240 of SEQ ID NO:25 represent the second complementarity determining region (CDR2); and nucleotides 337-363 of SEQ ID NO:25 represent the third complementarity determining region (CDR3). Within mAb 13.2 sub-clone 89-5's VH, nucleotides 133-162 of SEQ ID NO:26 represent the first complementarity determining region (CDR1); nucleotides 205-255 of SEQ ID NO:26 represent the second complementarity determining region (CDR2); and nucleotides 367-387 of SEQ ID NO:26 represent the third complementarity determining region (CDR3).
[0112] The corresponding predicted amino acid sequences of mAb 13.2 sub-clone 89-5's variable chain regions were also determined, and are designated SEQ ID NO:27 (light chain) and SEQ ID NO:28 (heavy chain). Within mAb 13.2 sub-clone 89-5's VL, amino acid residues 43-58 of SEQ ID NO:27 represent the first complementarity determining region (CDR1); amino acid residues 74-80 of SEQ ID NO:27 represent the second complementarity determining region (CDR2); and amino acid residues 113-121 of SEQ ID NO:27 represent the third complementarity determining region (CDR3). Within mAb 13.2 sub-clone 89-5's VH, amino acid residues 45-54 of SEQ ID NO:28 represent the first complementarity determining region (CDR1); amino acid residues 69-85 of SEQ ID NO:28 represent the second complementarity determining region (CDR2); and amino acid residues 123-129 of SEQ ID NO:28 represent the third complementarity determining region (CDR3).

EXAMPLE 4

Antibodies to Risperidone/Paliperidone

[0113] Antibody 5_9
[0114] The hybridoma designated 5_9 secretes a monoclonal antibody (mAb) specific for risperidone (and its metabolite paliperidone). The antibody is designated 5-9. The nucleotide sequence of mAb 5-9's light chain variable region (VL) is designated SEQ ID NO:1 and that of the heavy chain variable region (VH) is designated SEQ ID NO:2. Within mAb 5-9's VL, nucleotides 130-180 of SEQ ID NO:1 represent the first complementarity determining region (CDR1); nucleotides 226-246 of SEQ ID NO:1 represent the second complementarity determining region (CDR2); and nucleotides 343-369 of SEQ ID NO:1 represent the third complementarity determining region (CDR3). Within mAb 5-9's VH, nucleotides 133-162 of SEQ ID NO:2 represent the first complementarity determining region (CDR1); nucleotides 205-255 of SEQ ID NO:2 represent the second complementarity determining region (CDR2); and nucleotides 352-366 of SEQ ID NO:2 represent the third complementarity determining region (CDR3).
[0115] The corresponding predicted amino acid sequences of mAb 5-9's variable chain regions were also determined, and are designated SEQ ID NO:3 (light chain) and SEQ ID NO:4 (heavy chain). Within mAb 5-9's VL, amino acid residues 44-60 of SEQ ID NO:3 represent the first complementarity determining region (CDR1); amino acid residues 76-82 of SEQ ID NO:3 represent the second complementarity determining region (CDR2); and amino acid residues 115-123 of SEQ ID NO:3 represent the third complementarity determining region (CDR3). Within mAb 5-9's VH, amino acid residues 45-54 of SEQ ID NO:4 represent the first complementarity determining region (CDR1); amino acid residues 69-85 of SEQ ID NO:4 represent the second complementarity determining region (CDR2); and amino acid residues 118-122 of SEQ ID NO:4 represent the third complementarity determining region (CDR3).
[0116] Antibody 5_5
[0117] The hybridoma designated 5_5 secretes a monoclonal antibody (mAb) specific for risperidone (and its metabolite paliperidone). The antibody is designated 5-5. The nucleotide sequence of mAb 5-5's light chain variable region (VL) is designated SEQ ID NO:5 and that of the heavy chain variable region (VH) is designated SEQ ID NO:6. Within mAb 5-5's VL, nucleotides 130-180 of SEQ ID NO:5 represent the first complementarity determining region (CDR1); nucleotides 226-246 of SEQ ID NO:5 represent the second complementarity determining region (CDR2); and nucleotides 343-369 of SEQ ID NO:5 represent the third complementarity determining region (CDR3). Within mAb 5-9's VH, nucleotides 133-162 of SEQ ID NO:6 represent the first complementarity determining region (CDR1); nucleotides 205-255 of SEQ ID NO:6 represent the second complementarity determining region (CDR2); and nucleotides 352-366 of SEQ ID NO:6 represent the third complementarity determining region (CDR3).
[0118] The corresponding predicted amino acid sequences of mAb 5-5's variable chain regions were also determined, and are designated SEQ ID NO:7 (light chain) and SEQ ID NO:8 (heavy chain). Within mAb 5-5's VL, amino acid residues 44-60 of SEQ ID NO:7 represent the first complementarity determining region (CDR1); amino acid residues 76-82 of SEQ ID NO:7 represent the second complementarity determining region (CDR2); and amino acid residues 115-123 of SEQ ID NO:7 represent the third complementarity determining region (CDR3). Within mAb 5-5's VH, amino acid residues 45-54 of SEQ ID NO:8 represent the first complementarity determining region (CDR1); amino acid residues 69-85 of SEQ ID NO:8 represent the second complementarity determining region (CDR2); and amino acid residues 118-122 of SEQ ID NO:8 represent the third complementarity determining region (CDR3).

EXAMPLE 5

Competitive Immunoassays for Risperidone/Paliperidone and Multiplex Competitive Immunoassay for Aripiprazole, Olanzapine, Quetiapine, and Risperidone/Paliperidone

[0119] Following a series of immunizations with paliperidone/risperidone immunogens, mouse tail bleeds were tested for reactivity using an ELISA. Hybridoma supernatants were also tested, and the ELISA data shown in Tables 1 and 2 below shows reactivity of several hybridomas (fusion partner was NSO cells). As shown in Table 2, reactivity of hybridomas 2A5 and 5G11 was seen.
[0120] 
[00001] [TABLE-US-00001]
  TABLE 1
 
  Dilution   1   2   3   4   5   6   7   8   9   10   11   12
 
  400   1   5   14   39   41   47   58   62   67   72   76   Blank   Ag = Bt-
  1200                           Compound#1
  3600
  10800
  400   1   5   14   39   41   47   58   62   67   72   76
  1200
  3600
  10800
  1
 
  Dilution   1   2   3   4   5   6
 
  400   3.2562   3.2897   3.3148   3.6038   0.6857   3.3976   Ag = Bt-
  1200   1.3591   1.4605   1.521   2.3063   0.1476   1.9245   Cmpd#1
  3600   0.3745   0.4617   0.3733   0.7613   0.038   0.6163
  10800   0.0918   0.1149   0.0908   0.1919   0.0156   0.1834
 
    Dilution  
    7   8   9   10   11   12
 
  400   1.3444   2.8639   0.5676   3.5993   2.5144   0.0143   Ag = Bt-
  1200   0.2841   1.0387   0.1158   2.6921   0.8711   0.0142   Cmpd#1
  3600   0.0689   0.2742   0.0304   0.9549   0.2236   0.0115
  10800   0.0199   0.0639   0.013   0.2766   0.056   0.0099
 
  Dilution   1   2   3   4   5   6
 
  400   3.1217   3.1103   3.1532   3.633   0.6089   3.5705   Ag = Bt-
  1200   1.2607   1.4817   1.3412   2.1411   0.1327   1.9831   Cmpd#1
  3600   0.3281   0.4159   0.3819   0.7373   0.0361   0.593
  10800   0.0879   0.1127   0.0929   0.1949   0.0156   0.189
 
  Dilution   7   8   9   10   11   12
 
  400   1.1067   2.4001   0.4963   3.4172   2.2432   0.0095   Ag = Bt-
  1200   0.2691   0.961   0.1027   2.5321   0.7418   0.0098   Cmpd#1
  3600   0.0723   0.292   0.0284   0.8426   0.2024   0.0079
  10800   0.0229   0.0722   0.0141   0.2393   0.052   0.0086
 
[0121] 
[00002] [TABLE-US-00002]
  TABLE 2
 
  Plate 1
    Dilution   1   2   3
   
    neat   Blank   1C4   6 E6
    neat     2A5   7A7
    neat     2G10   Empty
    neat     3B7
    neat     4D8
    neat     5A12
    neat     5G11
    neat     6C1
    neat   0.0072   0.038   0.0309
    neat   0.0077   3.9563   0.1163
    neat   0.0069   0.0093   0.0086
    neat   0.0076   0.0753   0.0108
    neat   0.0114   0.1139   0.0084
    neat   0.009   0.0193   0.0123
    neat   0.0087   0.2503   0.0085
    neat   0.0092   0.086   0.0121
   
[0122] After clones were identified via ELISA reactivity, competition ELISAs were run to approximate affinity and cross-reactivity with similar compounds. FIGS. 1 and 2 show the ELISA cross-reactivity results from hybridoma subclone 5_9. Data shows reactivity to risperidone, as well as its metabolites paliperidone and 7-hydroxyrisperidone.
[0123] Supernatants were also tested by competition ELISA to determine if the signals were specific to either risperidone or paliperidone. FIG. 3 shows the results from hybridoma subclone 2A5. Data shows reactivity to both risperidone and paliperidone.
[0124] FIG. 4 shows the competitive immunoassay format used on a lateral flow assay device in which the capture antibody, risperidone/paliperidone clone 5-9, was deposited on a chip along with a detection conjugate consisting of risperidone conjugated to a fluorophore. In this competitive format as show in FIG. 4, a low level of analyte (paliperidone) results in high signal, whereas a high level of analyte (paliperidone) results in low signal. The amount of paliperidone in the sample can be calculated from the loss of fluorescence compared to a control sample with no drug present. A typical dose response curve generated with risperidone/paliperidone clone 5-9 is shown in FIG. 5.
[0125] FIG. 6 shows the chip design of a lateral flow assay device according to one embodiment of the subject invention. The device includes a zone or area for receiving the sample, a conjugate zone (which contains desired labeled competitive binding partner(s)), and a reaction zone (eight areas within the reaction zone are indicated; each area can contain a separate desired antibody). Sample flows from the sample zone through the conjugate zone and to the reaction zone.
[0126] FIGS. 7-10 show typical dose response curves for an aripiprazole positive control (sample containing aripiprazole) generated with antibody 5C7 deposited in reaction zone 2 and a labeled aripiprazole competitive binding partner in the conjugate zone (FIG. 7), an olanzapine positive control (sample containing olanzapine) generated with antibody 4G9-1 deposited in reaction zone 4 and a labeled olanzapine competitive binding partner in the conjugate zone (FIG. 8), a quetiapine positive control (sample containing quetiapine) generated with antibody 11 deposited in reaction zone 6 and a labeled quetiapine competitive binding partner in the conjugate zone (FIG. 9), and a risperidone positive control (sample containing risperidone) generated with antibody 5-9 deposited in reaction zone 8 and a labeled risperidone competitive binding partner in the conjugate zone (FIG. 10). The labeled competitive binding partners in the conjugate zone compete with the drugs present in the samples for binding to the antibodies. The amount of label is detected and is an indication of the amount of drug present in the sample (the amount of signal being inversely proportional to the amount of drug in the sample—see FIG. 4).
[0127] In order to confirm that conjugates of labeled competitive binding partners do not bind to antibodies deposited in the reaction zones, negative controls were conducted by using samples containing no drugs. Referring to Table 3, a sample containing no aripiprazole is deposited in the sample zone and moves by capillary action through the conjugate zone (this time containing labeled olanzapine, labeled quetiapine, and labeled risperidone, but no labeled aripiprazole) and to the reaction zone. The reaction zone again contains aripiprazole antibody (5C7) in reaction zone 2. Table 3 below shows the results, confirming that there is no dose response and the olanzapine, quetiapine, and risperidone conjugates that move by capillary action through the reaction zone do not bind to the aripiprazole antibody.
[0128] 
[00003] [TABLE-US-00003]
  TABLE 3
 
  Aripiprazole-Clone 5C7-Math Model 1 (0 ng/mL Conc.)
      Reaction   Read   Peak Mean   Peak Mean   Mean
  Assay-MM   Conj   Zone   Position   Area   Height   Background
 
  ARIP-MM1   OLAN, QUET, RISP   ARIP   2   0.77   1.56   3.99
  ARIP-MM1   OLAN, QUET, RISP     4   −0.02   0.06   4.14
  ARIP-MM1   OLAN, QUET, RISP     6   0.09   0.10   4.29
  ARIP-MM1   OLAN, QUET, RISP     8   0.13   0.12   4.61
 
  Other Conjugates do not bind to Aripiprazole
[0129] Referring to Table 4, a sample containing no olanzapine is deposited in the sample zone and moves by capillary action through the conjugate zone (this time containing labeled aripiprazole, labeled quetiapine, and labeled risperidone, but no labeled olanzapine) and to the reaction zone. The reaction zone again contains olanzapine antibody (4G9-1) in reaction zone 4. Table 4 below shows the results, confirming that there is no dose response and the aripiprazole, quetiapine, and risperidone conjugates that move by capillary action through the reaction zone do not bind to the olanzapine antibody.
[0130] 
[00004] [TABLE-US-00004]
  TABLE 4
 
  OLAN-Clone 4G9-1-Math Model 1 (0 ng/mL Conc.)
      Reaction   Read   Peak Mean   Peak Mean   Mean
  Assay-MM   Conj   Zone   Position   Area   Height   Background
 
  OLAN-MM1   ARIP, QUET, RISP     2   −0.03   0.05   4.38
  OLAN-MM1   ARIP, QUET, RISP   OLAN   4   0.74   1.10   4.56
  OLAN-MM1   ARIP, QUET, RISP     6   0.06   0.09   4.79
  OLAN-MM1   ARIP, QUET, RISP     8   0.11   0.13   5.17
 
  Other Conjugates do not bind to Olanzapine
[0131] Referring to Table 5, a sample containing no quetiapine is deposited in the sample zone and moves by capillary action through the conjugate zone (this time containing labeled aripiprazole, labeled olanzapine, and labeled risperidone, but no labeled quetiapine) and to the reaction zone. The reaction zone again contains quetiapine antibody (11) in reaction zone 6. Table 5 below shows the results, confirming that there is no dose response and the aripiprazole, olanzapine, and risperidone conjugates that move by capillary action through the reaction zone do not bind to the quetiapine antibody.
[0132] 
[00005] [TABLE-US-00005]
  TABLE 5
 
  Quetiapine-Clone 11-Math Model 1 (0 ng/mL Conc.)
      Reaction   Read   Peak Mean   Peak Mean   Mean
  Assay-MM   Conj   Zone   Position   Area   Height   Background
 
  QUET-MM1   ARIP, OLAN, RISP     2   −0.01   0.07   3.85
  QUET-MM1   ARIP, OLAN, RISP     4   0.01   0.12   4.01
  QUET-MM1   ARIP, OLAN, RISP   QUET   6   0.03   0.08   4.24
  QUET-MM1   ARIP, OLAN, RISP     8   0.04   0.07   4.56
 
  Other Conjugates do not bind to Quetiapine
[0133] Referring to Table 6, a sample containing no risperidone is deposited in the sample zone and moves by capillary action through the conjugate zone (this time containing labeled aripiprazole, labeled olanzapine, and labeled quetiapine, but no labeled risperidone) and to the reaction zone. The reaction zone again contains risperidone antibody (5-9) in reaction zone 8. Table 6 below shows the results, confirming that there is no dose response and the aripiprazole, olanzapine, and quetiapine conjugates that move by capillary action through the reaction zone do not bind to the risperidone antibody.
[0134] 
[00006] [TABLE-US-00006]
  TABLE 6
 
  Risperidone-Clone 5-9-Math Model 1 (0 ng/mL Conc.)
      Reaction   Read   Peak Mean   Peak Mean   Mean
  Assay-MM   Conj   Zone   Position   Area   Height   Background
 
  RISP-MM1   ARIP, OLAN, QUET     2   0.02   0.11   7.43
  RISP-MM1   ARIP, OLAN, QUET     4   0.05   0.14   7.73
  RISP-MM1   ARIP, OLAN, QUET     6   0.20   0.19   8.11
  RISP-MM1   ARIP, OLAN, QUET   RISP   8   1.97   3.23   8.85
 
  Other Conjugates do not bind to Risperidone
[0135] In order to confirm that conjugates of labeled competitive binding partners bind only to their respective antibodies deposited in the reaction zones, additional negative controls were conducted by again using samples containing no drugs. Referring to Table 7, a sample containing no aripiprazole is deposited in the sample zone and moves by capillary action through the conjugate zone (this time containing labeled aripiprazole) and to the reaction zone. The reaction zone again contains aripiprazole antibody (5C7) in reaction zone 2, as well as olanzapine antibody (4G9-1) in reaction zone 4, quetiapine antibody (11) in reaction zone 6, and risperidone antibody (5-9) in reaction zone 8. Table 7 below shows the results, confirming that there is no dose response except to the aripiprazole antibody 5C7 (in reaction zone 2).
[0136] 
[00007] [TABLE-US-00007]
  TABLE 7
 
  Aripiprazole-Clone 5C7-Math Model 1 (0 ng/mL Conc.)
          Peak   Peak  
      Reaction     Mean   Mean   Mean
  Assay-MM   Conj   Zone   Read Position   Area   Height   Background
 
  ARIP-MM1   ARIP, OLAN, QUET, RISP   ARIP   2   60.34   97.53   5.44
  ARIP-MM1   ARIP, OLAN, QUET, RISP     4   2.86   3.91   11.66
  ARIP-MM1   ARIP, OLAN, QUET, RISP     6   1.12   1.23   11.03
  ARIP-MM1   ARIP, OLAN, QUET, RISP     8   3.14   4.19   12.94
 
  Only the Aripiprazole Reaction Zone is binding
[0137] Referring to Table 8, a sample containing no olanzapine is deposited in the sample zone and moves by capillary action through the conjugate zone (this time containing labeled olanzapine) and to the reaction zone. The reaction zone again contains aripiprazole antibody (5C7) in reaction zone 2, as well as olanzapine antibody (4G9-1) in reaction zone 4, quetiapine antibody (11) in reaction zone 6, and risperidone antibody (5-9) in reaction zone 8. Table 8 below shows the results, confirming that there is no dose response except to the olanzapine antibody 4G9-1 (in reaction zone 4).
[0138] 
[00008] [TABLE-US-00008]
  TABLE 8
 
  OLAN-Clone 4G9-1-Math Model 1 (0 ng/mL Conc.)
          Peak   Peak  
      Reaction     Mean   Mean   Mean
  Assay-MM   Conj   Zone   Read Position   Area   Height   Background
 
  OLAN-MM1   ARIP, OLAN, QUET, RISP     2   0.02   0.08   4.86
  OLAN-MM1   ARIP, OLAN, QUET, RISP   OLAN   4   34.23   51.80   5.39
  OLAN-MM1   ARIP, OLAN, QUET, RISP     6   0.22   0.32   5.39
  OLAN-MM1   ARIP, OLAN, QUET, RISP     8   0.15   0.17   5.59
 
  Only the Olanzapine Reaction Zone is binding
[0139] Referring to Table 9, a sample containing no quetiapine is deposited in the sample zone and moves by capillary action through the conjugate zone (this time containing labeled quetiapine) and to the reaction zone. The reaction zone again contains aripiprazole antibody (5C7) in reaction zone 2, as well as olanzapine antibody (4G9-1) in reaction zone 4, quetiapine antibody (11) in reaction zone 6, and risperidone antibody (5-9) in reaction zone 8. Table 9 below shows the results, confirming that there is no dose response except to the quetiapine antibody 11 (in reaction zone 6).
[0140] 
[00009] [TABLE-US-00009]
  TABLE 9
 
  Quetiapine-Clone 11-Math Model 1 (0 ng/mL Conc.)
          Peak   Peak  
      Reaction     Mean   Mean   Mean
  Assay-MM   Conj   Zone   Read Position   Area   Height   Background
 
  QUET-MM1   ARIP, OLAN, QUET, RISP     2   0.13   0.41   10.02
  QUET-MM1   ARIP, OLAN, QUET, RISP     4   0.08   0.23   10.47
  QUET-MM1   ARIP, OLAN, QUET, RISP   QUET   6   140.35   181.33   7.91
  QUET-MM1   ARIP, OLAN, QUET, RISP     8   1.58   2.61   11.53
 
  Only the Quetiapine Reaction Zone is binding
[0141] Referring to Table 10, a sample containing no risperidone is deposited in the sample zone and moves by capillary action through the conjugate zone (this time containing labeled risperidone) and to the reaction zone. The reaction zone again contains aripiprazole antibody (5C7) in reaction zone 2, as well as olanzapine antibody (4G9-1) in reaction zone 4, quetiapine antibody (11) in reaction zone 6, and risperidone antibody (5-9) in reaction zone 8. Table 10 below shows the results, confirming that there is no dose response except to the risperidone antibody 5-9 (in reaction zone 8).
[0142] 
[00010] [TABLE-US-00010]
  TABLE 10
 
  Risperidone-Clone 5-9-Math Model 1 (0 ng/mL Conc.)
          Peak   Peak  
      Reaction     Mean   Mean   Mean
  Assay-MM   Conj   Zone   Read Position   Area   Height   Background
 
  RISP-MM1   ARIP, OLAN, QUET, RISP     2   1.03   1.51   9.07
  RISP-MM1   ARIP, OLAN, QUET, RISP     4   0.65   0.91   9.60
  RISP-MM1   ARIP, OLAN, QUET, RISP     6   2.61   6.39   10.48
  RISP-MM1   ARIP, OLAN, QUET, RISP   RISP   8   55.98   100.91   11.58
 
  Only the Risperidone Reaction Zone is binding
[0143] The results shown above confirm that conjugates of labeled competitive binding partners bind only to their respective antibodies in the reaction zone.
[0144] FIGS. 11-14 show typical dose response curves in specific antibody reaction zones, and proof of dose response low/high concentration for each specific assay in the presence of other conjugates. In FIG. 11, a sample containing aripiprazole is deposited in the sample zone and moves by capillary action through the conjugate zone (this time containing labeled aripiprazole, labeled olanzapine, labeled quetiapine, and labeled risperidone) and to the reaction zone. The reaction zone again contains aripiprazole antibody (5C7) in reaction zone 2. A typical dose response curve was generated as is shown in FIG. 11 only for aripiprazole, and not for olanzapine, quetiapine, or risperidone.
[0145] In FIG. 12, a sample containing olanzapine is deposited in the sample zone and moves by capillary action through the conjugate zone (this time containing labeled aripiprazole, labeled olanzapine, labeled quetiapine, and labeled risperidone) and to the reaction zone. The reaction zone again contains olanzapine antibody (4G9-1) in reaction zone 4. A typical dose response curve was generated as is shown in FIG. 12 only for olanzapine, and not for aripiprazole, quetiapine, or risperidone.
[0146] In FIG. 13, a sample containing quetiapine is deposited in the sample zone and moves by capillary action through the conjugate zone (this time containing labeled aripiprazole, labeled olanzapine, labeled quetiapine, and labeled risperidone) and to the reaction zone. The reaction zone again contains quetiapine antibody (11) in reaction zone 6. A typical dose response curve was generated as is shown in FIG. 13 only for quetiapine, and not for aripiprazole, olanzapine, or risperidone.
[0147] In FIG. 14, a sample containing risperidone is deposited in the sample zone and moves by capillary action through the conjugate zone (this time containing labeled aripiprazole, labeled olanzapine, labeled quetiapine, and labeled risperidone) and to the reaction zone. The reaction zone again contains risperidone antibody (5-9) in reaction zone 8. A typical dose response curve was generated as is shown in FIG. 14 only for risperidone, and not for aripiprazole, olanzapine, or quetiapine.
[0148] FIGS. 15-18 show typical dose response curves for each assay in the presence of other conjugates and antibodies. In FIG. 15, a sample containing aripiprazole is deposited in the sample zone and moves by capillary action through the conjugate zone (again containing labeled aripiprazole, labeled olanzapine, labeled quetiapine, and labeled risperidone) and to the reaction zone. The reaction zone again contains aripiprazole antibody (5C7) in reaction zone 2, as well as olanzapine antibody (4G9-1) in reaction zone 4, quetiapine antibody (11) in reaction zone 6, and risperidone antibody (5-9) in reaction zone 8. A typical dose response curve was generated for aripiprazole, as is shown in FIG. 15. When a sample containing olanzapine was deposited in the sample zone of this chip, a typical dose response curve was generated for olanzapine as shown in FIG. 16. When a sample containing quetiapine was deposited in the sample zone of this chip, a typical dose response curve for quetiapine was generated as shown in FIG. 17. When a sample containing risperidone was deposited in the sample zone of this chip, a typical dose response curve for risperidone was generated as shown in FIG. 18.
[0149] FIGS. 19-22 show comparisons of dose response curves generated as positive controls (FIGS. 7-10) to dose response curves generated in the multiplex format (FIGS. 15-18). The comparison for aripiprazole is shown in FIG. 19; for olanzapine in FIG. 20; for quetiapine in FIG. 21; and for risperidone in FIG. 22. These figures show that the positive control curves are similar to the multiplex curves.
[0150] These data show that a lateral flow assay device of the subject invention can be used to detect multiple anti-psychotic drugs using a single sample from a patient on one portable, point-of-care device.
(57)

Claims

1. An isolated antibody or a binding fragment thereof, which specifically binds to paliperidone and which said isolated antibody or binding fragment thereof is selected from the group of amino acid sequences consisting of:
a) the isolated antibody or the binding fragment thereof comprising a heavy chain variable region, and a light chain variable region wherein said light chain variable region comprising an amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7;
b) the isolated antibody or the binding fragment thereof comprising a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:4 or SEQ ID NO:8, and a light chain variable region;
c) the isolated antibody or the binding fragment thereof comprising a light chain variable region having an amino acid sequence of SEQ ID NO:3 and a heavy chain variable region having an amino acid sequence of SEQ ID NO:4; or
d) the isolated antibody or the binding fragment thereof comprising a light chain variable region having an amino acid sequence of SEQ ID NO:7 and a heavy chain variable region having an amino acid sequence of SEQ ID NO:8.
2. The isolated antibody of claim 1, wherein the antibody comprises the light chain variable region having the amino acid sequence SEQ ID NO:3 and the heavy chain variable region having the amino acid sequence SEQ ID NO:4.
3. The isolated antibody of claim 1, wherein the antibody comprises the light chain variable region having the amino acid sequence SEQ ID NO:7 and the heavy chain variable region having the amino acid sequence SEQ ID NO:8.
4. The isolated antibody of claim 1, wherein the antibody comprises:
a) a light chain CDR1 sequence comprising amino acid residues 44 to 60 of SEQ ID NO:3;
b) a light chain CDR2 sequence comprising amino acid residues 76 to 82 of SEQ ID NO:3;
c) a light chain CDR3 sequence comprising amino acid residues 115 to 123 of SEQ ID NO:3;
d) a heavy chain CDR1 sequence comprising amino acid residues 45 to 54 of SEQ ID NO:4;
e) a heavy chain CDR2 sequence comprising amino acid residues 69 to 85 of SEQ ID NO:4; and
f) a heavy chain CDR3 sequence comprising amino acid residues 118 to 122 of SEQ ID NO:4.
5. The isolated antibody of claim 1, wherein the antibody comprises:
a) a light chain CDR1 sequence comprising amino acid residues 44 to 60 of SEQ ID NO:7;
b) a light chain CDR2 sequence comprising amino acid residues 76 to 82 of SEQ ID NO:7;
c) a light chain CDR3 sequence comprising amino acid residues 115 to 123 of SEQ ID NO:7;
d) a heavy chain CDR1 sequence comprising amino acid residues 45 to 54 of SEQ ID NO:8;
e) a heavy chain CDR2 sequence comprising amino acid residues 69 to 85 of SEQ ID NO:8; and
f) a heavy chain CDR3 sequence comprising amino acid residues 118 to 122 of SEQ ID NO:8.
6. The isolated antibody of claim 1, wherein the antibody fragment is selected from the group of fragments consisting of Fv, F(ab'), F(ab')2, scFv, minibody and diabody fragments.
7. The isolated antibody of claim 1, wherein the antibody is a monoclonal antibody.
8. An assay kit comprising the isolated antibody of claim 1.
9. An assay device comprising the isolated antibody of claim 1.
10. The assay device of claim 9 wherein the device is a lateral flow assay device.
11. A method of detecting paliperidone in a sample, the method comprising:
(i) contacting a sample with the isolated antibody of claim 1 labeled with a detectable marker, wherein the labeled antibody and paliperidone present in the sample form a labeled complex; and
(ii) detecting the labeled complex so as to detect paliperidone in the sample.
12. A competitive immunoassay method for detecting paliperidone in a sample, the method comprising:
(i) contacting a sample with the isolated antibody of claim 1, and with paliperidone or a competitive binding partner thereof, wherein one of the isolated antibody and the paliperidone or competitive binding partner thereof is labeled with a detectable marker, and wherein sample paliperidone competes with the paliperidone or competitive binding partner thereof for binding to the isolated antibody; and
(ii) detecting the label so as to detect sample paliperidone.
13. The method of claim 12 wherein the paliperidone or competitive binding partner thereof is labeled with the detectable marker.
14. The method of claim 12 wherein the antibody is labeled with a detectable marker.
15. The method of claim 12 wherein the immunoassay is performed on a lateral flow assay device and the sample is applied to the device.
16. The method of claim 11 or 12, further comprising detecting the presence of one or more analytes in addition to paliperidone.
17. The method of claim 16 wherein the one or more analytes are anti-psychotic drugs other than paliperidone.
18. The method of claim 17 wherein the anti-psychotic drugs other than paliperidone are selected from the group consisting of: risperidone, quetiapine, olanzapine, aripiprazole, and metabolites thereof.
*****

Sign in to the Lens